via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASMR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 28	CA/CAplus patent coverage enhanced
NEWS 3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5	JUL 28	STN Viewer performance improved
NEWS 6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 9	AUG 15	CAplus currency for Korean patents enhanced
NEWS 10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 12	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 14	SEP 29	IFICLS enhanced with new super search field
NEWS 15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS 19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS 20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:30:00 ON 27 OCT 2008

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 11:30:38 ON 27 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 OCT 2008 HIGHEST RN 1065816-63-8
DICTIONARY FILE UPDATES: 24 OCT 2008 HIGHEST RN 1065816-63-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\STNEXP\Queries\10564010 str 2.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d 12
L2 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

=> s l2 sss full
FULL SEARCH INITIATED 11:30:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1577 TO ITERATE

100.0% PROCESSED 1577 ITERATIONS 22 ANSWERS
SEARCH TIME: 00.00.01

L3 22 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 11:31:05 ON 27 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Oct 2008 VOL 149 ISS 18
FILE LAST UPDATED: 26 Oct 2008 (20081026/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3

```
L4          22 L3

=> s l4 and py<=2004
      25113423 PY<=2004
L5          16 L4 AND PY<=2004

=> d l5 1-16 ibib ab hitstr

L5   ANSWER 1 OF 16  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2003:836594  CAPLUS
DOCUMENT NUMBER:          139:323523
TITLE:                    Preparation of aryloxycarbamoylazoles as calcium
                          channel blockers
INVENTOR(S):              Snutch, Terrance P.
PATENT ASSIGNEE(S):       Can.
SOURCE:                   U.S. Pat. Appl. Publ., 22 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
     US 20030199523       A1    20031023    US 2003-377090          20030228 <--
PRIORITY APPLN. INFO.:                      US 2002-360917P     P   20020228
OTHER SOURCE(S):          MARPAT 139:323523
AB   ArXQ, Ar2CHXQ [Ar = 6-membered (substituted) aryl containing ≥1 S, O
     and N, optionally coupled through O to the linker X; X = (substituted)
     alkylene of 2-10 sequentially connected atoms selected from C, N, O, and
     S; Q = 5-membered (substituted) heterocyclyl containing ≥1 N or S
     atom], were prepared  Thus, O-benzotriazolyl-N,N,N',N'-tetramethyluronium
     tetrafluoroborate was added to a solution of
     2-(4,4'-dichlorobenzhydryl)acetic acid, 2-amino-5-nitrothiazole, and Et3N
     in CH2Cl2/MeCN and the reaction mixture was stirred at room temperature
overnight
     to give N-2-(5-nitrothiazolyl)-2-(4,4'-dichlorobenzhydryl)acetic amide (NT
     051).  NT 051 blocked α1B, α1A, and α1C channels with
     IC50 = 0.13 μM, 6.8 μM, and 1.91 μM, resp.
IT   615283-83-5
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (preparation of aryloxycarbamoylazoles as calcium channel blockers)
RN   615283-83-5  CAPLUS
CN   Acetamide, 2-(2,4-dichlorophenoxy)-N-(4,5-dicyano-1H-imidazol-2-yl)-  (CA
     INDEX NAME)
```




```
L5   ANSWER 2 OF 16  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2003:532641  CAPLUS
DOCUMENT NUMBER:          139:101147
```

TITLE: Preparation of aromatic hydrocarbon-fused heterocyclic dithiols and disulfides as electron-accepting compounds capable of forming self-assembled monolayers

INVENTOR(S): Saso, Haruo; Satoh, Toshiaki; Takahashi, Toshiaki; Ogawa, Satoshi; Yoshimoto, Noriyuki

PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan

SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055853	A1	20030710	WO 2002-JP13590	20021226 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002357515	A1	20030715	AU 2002-357515	20021226 <--

PRIORITY APPLN. INFO.:

JP 2001-394984	A	20011226
JP 2002-40385	A	20020218
WO 2002-JP13590	W	20021226

OTHER SOURCE(S): MARPAT 139:101147

AB The compds. represented by the general formula A-Sp-X [wherein A is (i) an aromatic heterocyclic group bearing at least one member selected from the group consisting of cyano, C1-6 alkoxycarbonyl, and C1-11 acyl either on the ring or in a state attached to the ring through a conjugated system or (ii) an electron-accepting functional group to which at least one aromatic hydrocarbon ring is fused; Sp is a divalent connecting group containing an arylene group and/or an alkylene group; and X is a binding group capable of making a connection to a metal surface, a metal oxide surface, or a semiconductor surface by a covalent or coordinate bond] are prepared These Compds. have simple structures and are easy of preparation and have the ability to accept an electron and can be self-assembled to form monolayers easily. They are useful as raw materials for mol. devices. Thus, a mixture of naphthalene-1,4,5,8-tetracarboxylic acid dianhydride 5.36, 5-hydroxy-1-pentylamine 4.54, p-toluenesulfonic acid 0.19 g, and 100 mL toluene was refluxed for 8 h with removing H2O though a Dean Stark trap to give 87% N,N'-bis(5-hydroxypentyl)-1,4,5,8-naphthalenetetracarboxylic diimide (I). I (2.02 g) and 3.26 g PBr3 were refluxed in the presence of a catalytic amount of pyridine in 100 mL toluene for 7 h to give 2.65 g crude N,N'-bis(5-bromopentyl)-1,4,5,8-naphthalenetetracarboxylic diimide which was dissolved in 50 mL CHCl3, successively treated with 1.66 g Bu4NBr and aqueous solution of 1.30 g potassium thiosulfate in 20 mL H2O and stirred at room temperature for 25 h to give 81% N,N'-bis(5-acetylthiopentyl)-1,4,5,8-naphthalenetetracarboxylic diimide (II). II (3.21 g) was suspended in 100 MeOH, treated with 10 mL concentrated HCl, and heated under refluxed for 7 days to give 29% N,N'-bis(5-mercaptopentyl)-1,4,5,8-naphthalenetetracarboxylic diimide (III). A gold electrode (1.6 mm diameter) for cyclic voltammetry was immersed in 0.1 mM III/EtOH for 24 h, and successively washed with ethanol and MeCN. A reduction potential of -1.33 V was observed using a Ag/AgNO3 reference

electrode and a Pt electrode against the gold electrode prepared above, which confirmed the formation of a thin film on the gold surface.

IT 556815-13-5P
RL: DEV (Device component use); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(preparation of aromatic hydrocarbon-fused heterocyclic dithiols and disulfides as electron-accepting compds. capable of forming self-assembled monolayers)

RN 556815-13-5 CAPLUS

CN 1,2-Dithiolane-3-hexanamide, N-(4,5-dicyano-1H-imidazol-2-yl)- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:888725 CAPLUS
DOCUMENT NUMBER: 137:384838
TITLE: Heterocycle-substituted amides as protease inhibitors
INVENTOR(S): Cardel, Bettina; Metz, Guenther; Ottleben, Holger; Rau, Harald; Schellhaas, Nathalie; Sekul, Renate; Vetter, Dirk; Bode, Wolfram; Friedrich, Rainer
PATENT ASSIGNEE(S): Graffinity Pharmaceuticals A.-G., Germany
SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092582	A1	20021121	WO 2002-EP5369	20020515 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10124041	A1	20021121	DE 2001-10124041	20010516 <--
AU 2002304630	A1	20021125	AU 2002-304630	20020515 <--
EP 1387833	A1	20040211	EP 2002-732716	20020515 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			DE 2001-10124041	A 20010516
			WO 2002-EP5369	W 20020515

OTHER SOURCE(S): MARPAT 137:384838

AB ADCR1R2COXCHYEZ [A = (un)substituted aryl, cycloalkyl, cycloalkenyl; D =

O, S, S(O), SO2; R1, R2 = NO2, (un)substituted alkyl, alkoxy, acyl, alkoxycarbonyl, acyloxy, NH2, CONH2, cycloalkyl, aryl, benzyl; X = O, S, (un)substituted NH; Y = (un)substituted aryl, cycloalkyl, cycloalkenyl, alkyl, alkoxy, acyl; E, Z = H, F, Cl, Br, I, OH, SH, CF3, NO2, acyl, (un)substituted CO2H, acyloxy, alkyl, alkoxy, NH2, CONH2, aryl, cycloalkyl, cycloalkenyl, bicycloalkenyl; EZ = (un)substituted CONH2] were prepared for use as inhibitors of proteases, especially serine proteases such as thrombin. Thus, the diamide I was prepared from polymer-supported 4-H2NSO2C6H4CO2H, N-9-fluorenylmethoxycarbonyl-L-4-thiazolylalanine, 4-ClC6H4SCH2CO2H, and histamine by solid-phase synthesis. I had Ki for inhibition of thrombin activity of 6X10-6 M.

IT 475680-12-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocycle-substituted amides as inhibitors of thrombin and factor X)

RN 475680-12-7 CAPLUS

CN 4-Thiazolepropanamide, α-[[2-[(4-chlorophenyl)thio]acetyl]amino]-N-(4,5-dicyano-1H-imidazol-2-yl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:855867 CAPLUS

DOCUMENT NUMBER: 139:214346

TITLE: Product class 3: imidazoles

AUTHOR(S): Grimmett, M. R.

CORPORATE SOURCE: Organic Chemistry, Dept. of Chemistry, University of Otago, Dunedin, N. Z.

SOURCE: Science of Synthesis (2002), 12, 325-528
CODEN: SSCYJ9

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Methods for preparing imidazoles are reviewed including cyclization, ring transformations, aromatization and modification of substituents on existing imidazoles.

IT 40639-97-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazoles via cyclization, ring transformation, aromatization and substituent modifications)

RN 40639-97-2 CAPLUS

CN Acetamide, N-(4,5-dimethyl-1H-imidazol-2-yl)- (CA INDEX NAME)



REFERENCE COUNT: 823 THERE ARE 823 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:827797 CAPLUS
DOCUMENT NUMBER: 137:331022
TITLE: Coupler for azomethine dye formation and silver halide photographic material using it
INVENTOR(S): Ogasawara, Atsushi; Kamihira, Shigeo; Shimada, Yasuhiro
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002318441	A	20021031	JP 2001-123651	20010420 <--

PRIORITY APPLN. INFO.: JP 2001-123651 20010420
OTHER SOURCE(S): MARPAT 137:331022
AB Dye forming coupler I and azomethine dye II (Q = nonmetal atoms to form N-containing heterocycle; R = substituent; Het = heterocycle; X = H, releasing group by coupling reaction with developer oxide; Ar = aryl) are claimed. The azomethine dye shows high mol. extinction coeff, clear hue, and the photog. material gives clear images with good fastness.
IT 473738-67-9P
RL: PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(azomethine dye; photog. coupler for azomethine dye formation)
RN 473738-67-9 CAPLUS
CN Benzoic acid, 3,3'-[[2-[[[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl][[4-[ethyl[2-[(methylsulfonyl)amino]ethyl]amino]-2-methylphenyl]imino]acetyl]amino]-1H-imidazole-4,5-diyl]bis(carbonylimino)]bis[4-chloro-, didodecyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 473738-53-3P
RL: PNU (Preparation, unclassified); RCT (Reactant); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(photog. coupler for azomethine dye formation)

RN 473738-53-3 CAPLUS

CN Benzoic acid, 3,3'-[[2-[[[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl](3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)acetyl]amino]-1H-imidazole-4,5-diyl]bis(carbonylimino)]bis[4-chloro-, didodecyl ester (9CI) (CA INDEX NAME)



IT 473738-63-5
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler for azomethine dye formation)
RN 473738-63-5 CAPLUS
CN 4H-1,2,4-Benzothiadiazine-3-acetamide,
α-(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)-N-(4,5-dimethyl-1H-imidazol-2-yl)-4-dodecyl-, 1,1-dioxide (CA INDEX NAME)



IT 473738-75-9P
RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation of photog. coupler)
RN 473738-75-9 CAPLUS
CN Benzoic acid, 3,3'-[[2-[[bromo[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]acetyl]amino]-1H-imidazole-4,5-diyl]bis(carbonylimino)]bis[4-chloro-, didodecyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:682235 CAPLUS
DOCUMENT NUMBER: 129:302639
ORIGINAL REFERENCE NO.: 129:61735a,61738a
TITLE: Preparation of imidazolylaminopropylindazolylcarbonylaminopropionate ammonioalkyl esters and related compounds as integrin αvβ3 inhibitor prodrugs.
INVENTOR(S): Jadhav, Prabhakar; Batt, Douglas G.; Hussain, Munir A.; Pitts, William J.; Repta, Arnold J.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Co., USA
SOURCE: PCT Int. Appl., 311 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9843962	A1	19981008	WO 1998-US6054	19980327 <--
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9867803	A	19981022	AU 1998-67803	19980327 <--
US 6214834	B1	20010410	US 1998-49305	19980327 <--
PRIORITY APPLN. INFO.:			US 1997-41759P P	19970328
			WO 1998-US6054 W	19980327

OTHER SOURCE(S): MARPAT 129:302639
AB Title compds. [I; X1-X4 = N, C; ≥2 of X1-X4 = C; R1 = specified heterocyclylalkyl; R10 = H, amino, halo, NO2, cyano, CF3, sulfonylamino, carbamoyl, (substituted) alkyl, alkoxy, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, etc.; R11 = H, halo, CF3, cyano, NO2, OH, amino, (substituted) alkyl, alkoxy, aryl, aralkyl, alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl, alkylaminosulfonyl; W = [C(R12)2]qCONR13, CONR13[C(R12)2]q; X = CR12R14CR12R15; WX = specified piperazinylcarbonyl(alkyl); Y = COR19; R12 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, alkylcarbonyl, aryl, aralkyl; R13 = H, (substituted) alkyl, cycloalkylmethyl, aralkyl; R14 = H,

alkylthioalkyl, aralkylthioalkyl, aralkoxyalkyl, alkyl, alkoxyalkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, heteroarylalkyl, aryl, heteroaryl, etc.; R15 = H, (substituted) alkyl, alkoxyalkyl, alkylaminoalkyl, aralkylcarbonyl, aryl, heteroaryl, heteroarylalkyl, aminosulfonyl, aminosulfonylamino, etc.; R19 = O(CH2)kN+R22R23R24 Z-; Z- = specified pharmaceutically acceptable anion; R22-R24 = H, (substituted) alkyl, cyclolalkylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl; R22R23 = (substituted) 5-7 membered heterocyclyl; R22R23R24 = (substituted) heterobicyclyl; q = 0-2; k = 2-6], were prepared I may be administered by iontophoresis for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis. Thus, title compound (II; R = CH2CH2N+Me3) showed electrophoretic mobility = 3.2 cm2/V/s at pH 4.5, vs. 1.7 cm2/V/s for II (R = Me).

IT 185561-98-2DP, esters with ammonioalkanols
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolylaminopropylindazolylcarbonylaminopropionate ammonioalkyl esters and related compds. as integrin inhibitor prodrugs)

RN 185561-98-2 CAPLUS

CN Alanine, 3-[[[3-[4-[(4,5-dimethyl-1H-imidazol-2-yl)amino]-4-oxobutyl]-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:76956 CAPLUS
DOCUMENT NUMBER: 126:89390
ORIGINAL REFERENCE NO.: 126:17263a,17266a
TITLE: Preparation of cyclic amides as herbicides
INVENTOR(S): Takabe, Fumiaki; Ichinohe, Yuki; Shibayama, Atsushi; Yamaguchi, Mikio; Yanagisawa, Katsutada; Ogawa, Yasunori; Sadohara, Hideo
PATENT ASSIGNEE(S): Kumiai Chemical Industry Co, Japan; Ihara Chemical Ind Co
SOURCE: Jpn. Kokai Tokkyo Koho, 37 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08311026	A	19961126	JP 1996-69068	19960229 <--
JP 3954127	B2	20070808		
JP 2007182456	A	20070719	JP 2007-86387	20070329
PRIORITY APPLN. INFO.:			JP 1995-81967 A	19950314
			JP 1996-69068 A3	19960229

OTHER SOURCE(S): MARPAT 126:89390
AB The title compds. I [AB = NNMe, etc.; X = H, halo, etc.; m = 1 or 2; n = 1 - 3; R1 = carbamoyl with substituent, etc.] are prepared The title compound II (at 10 g) gave ≥ 90% control of Monochoria vaginalis and Scirpus juncoides.
IT 185693-68-9P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amides as herbicides)
RN 185693-68-9 CAPLUS
CN 1H-Pyrrole-1-acetamide, N-(4,5-dicyano-1H-imidazol-2-yl)-2,5-dihydro-α,α,4-trimethyl-2-oxo-3-phenyl- (CA INDEX NAME)



L5 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:69816 CAPLUS
DOCUMENT NUMBER: 126:89360
ORIGINAL REFERENCE NO.: 126:17255a,17258a
TITLE: Preparation of [(isoxazolinylalkanoyl)amino]alkanoates and analogs as integrin antagonists
INVENTOR(S): Voss, Matthew Ernst; Jadhav, Prabhakar Kondaji; Smallheer, Joanne Marie; Batt, Douglas Guy; Pitts, William John; Wityak, John
PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Company, USA

SOURCE: PCT Int. Appl., 331 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9637492	A1	19961128	WO 1996-US7646	19960524 <--
W: AM, AT, AU, AZ, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, JP, KG, KR, KZ, LT, LU, LV, MD, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, UA, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5710159	A	19980120	US 1996-647132	19960509 <--
CA 2221980	A1	19961128	CA 1996-2221980	19960524 <--
AU 9658762	A	19961211	AU 1996-58762	19960524 <--
ZA 9604195	A	19971124	ZA 1996-4195	19960524 <--
EP 828737	A1	19980318	EP 1996-920476	19960524 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11506436	T	19990608	JP 1996-535899	19960524 <--

PRIORITY APPLN. INFO.:
US 1995-450646 A 19950525
US 1995-455768 A 19950531
US 1996-647132 A 19960509
WO 1996-US7646 W 19960524

OTHER SOURCE(S): MARPAT 126:89360

AB Title compds. [(addnl.-substituted) I; R2 = Z2Z1R1; R1 = N-containing heterocyclyl; R3 = Z3ZR; R = CO2H, alkoxycarbonyl, SO3H, CONHNHSO2CF3, etc.; Z = bond (un)substituted alkylene; Z1 = bond, (O- or N-interrupted)alkylene, CO, alkanoyl(alkyl), NHCO, etc.; Z2 = bond, alkylene, phenylene, etc.; Z3 = (alkylene)carbonylimino(alkyl), etc.; dashed line = optional bond] were prepared as integrin antagonists (no data). Thus, R4(CH2)3CH:NOH (R4 = phthalimido)(preparation given) was chlorinated and the product cyclocondensed with CH2:CHCH2CO2CMe3 to give, after deprotection, tert-Bu 3-(3-aminopropyl)-2-isoxazoline-5-acetate. The latter was N-alkylated with 2-methylthio-3,4,5,6-tetrahydropyrimidine hydroiodide to give, after saponification, amidation by H2NCH2CH(NHSO2Ph)CO2Me, and saponification, title compound II.

IT 185561-98-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(isoxazolinylalkanoyl)amino]alkanoates and analogs as integrin antagonists)

RN 185561-98-2 CAPLUS

CN Alanine, 3-[[[3-[4-[(4,5-dimethyl-1H-imidazol-2-yl)amino]-4-oxobutyl]-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L5 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:183280 CAPLUS
DOCUMENT NUMBER: 122:55805
ORIGINAL REFERENCE NO.: 122:10814h,10815a
TITLE: A Simple and Practical Synthesis of 2-Aminoimidazoles
AUTHOR(S): Little, Thomas L.; Webber, Stephen E.
CORPORATE SOURCE: Agouron Pharmaceuticals Inc., San Diego, CA, 92121, USA
SOURCE: Journal of Organic Chemistry (1994), 59(24), 7299-305
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 122:55805

AB A new and simple two-step procedure to synthesize 2-aminoimidazoles (2-AI's) from readily available materials has been developed. The cyclization reaction of α-halo ketones RCOCHR1X [R = Me, Et, CMe3, Ph, 4-BrC6H4, etc., R1 = H, Me, Ph, RR1 = (CH2)3, (CH2)4, X = Cl, Br] and N-acetylguanidine in acetonitrile (MeCN) at reflux, or in DMF at ambient temperature, gives 4(5)-substituted and 4,5-disubstituted N-(1H-imidazol-2-yl)acetamides I, which are then hydrolyzed to their resp. 2-AI's. In general, the purified products were isolated in good yields. We have prepared several examples and have demonstrated the usefulness of this method by its application in the total synthesis of 2-aminohistamine, an interesting histamine analog, and oroidin (II), a marine natural product isolated from various sponges.

IT 40639-97-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminoimidazoles, aminohistamine, and oroidin by cyclization of carbonyl with acetylguanidine)
RN 40639-97-2 CAPLUS
CN Acetamide, N-(4,5-dimethyl-1H-imidazol-2-yl)- (CA INDEX NAME)



L5 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:105227 CAPLUS
DOCUMENT NUMBER: 88:105227
ORIGINAL REFERENCE NO.: 88:16505a,16508a
TITLE: Thiocarbonyl ylides of 1,3-diazacyclopentadiene and of cyclopentadiene
AUTHOR(S): Gronski, Peter; Hartke, Klaus
CORPORATE SOURCE: Inst. Pharm. Chem., Univ. Marburg, Marburg, Fed. Rep. Ger.
SOURCE: Chemische Berichte (1978), 111(1), 272-81
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 88:105227
AB R1R2NCSNR3R4 (R1-R4 = H, Me; R1 = Me, R2 = R4 = H, R3 = Me, R2-R4 = H, R2R3 = CH2CH2, R4 = H, Me, R2R3 = o-C6H4, R4 = Me; R1 = R4 = H, R2R3 = CH2CH2) reacted with imidazole I at room temperature to give 36-57% isothiuronium salts II (Z = bond) by elimination of N2. At 0°, 25-94% II (Z = N:N) were isolated as labile intermediates. Analogously, cyclopentadienide III (R5 = cyano, R6 = H) and N2NCSNH2 gave 8% isothiuronium salt IV (R1-R4, R6 = H, R5 = cyano); III (R5 = H, R6 = cyano) with R1R2NCSNR3R4 (R1 = R3 = H, R2 = R4 = Me; R1-R4 : Me; R1 = Me, R2R3 = CH2CH2, R4 = H, Me; R1 = R4 = Me; R2R3 = o-C6H4) gave 1.5-75% IV (R5 v H, R6 = cyano). Ylides II (Z = bond) and IV are thermally stable and are betaines.
IT 65739-60-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 65739-60-8 CAPLUS
CN Acetamide, N-(4,5-dicyano-1H-imidazol-2-yl)- (CA INDEX NAME)



L5 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:405638 CAPLUS

DOCUMENT NUMBER: 85:5638
ORIGINAL REFERENCE NO.: 85:907a,910a
TITLE: 2-Acylamino-4,5-di-cyanoimidazoles
INVENTOR(S): Segawa, Hirozo; Aida, Kazuhiko; Takagi, Toshiaki
PATENT ASSIGNEE(S): Kyowa Gas Chemical Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 51004171	A	19760114	JP 1974-74630	19740629 <--
PRIORITY APPLN. INFO.:			JP 1974-74630 A	19740629

AB The title imidazoles I (R1 = C1-16 alkyl, C6-14 aryl) were prepared by reacting II with RCOCl. Thus, 3.1 g p-MeC6H4COCl in THF was refluxed with 2.6 g II and pyridine in THF 2 hr to give I (R = C6H4Me-p). Among 6 more I similarly prepared were (R given); C6H4NO2-p, CH2Cl, CMe:CH2, CH2OPh.

IT 59380-96-0P 59380-97-1P 59380-98-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59380-96-0 CAPLUS
CN Acetamide, 2-chloro-N-(4,5-dicyano-1H-imidazol-2-yl)- (CA INDEX NAME)



RN 59380-97-1 CAPLUS
CN 2-Propenamide, N-(4,5-dicyano-1H-imidazol-2-yl)-2-methyl- (CA INDEX NAME)



RN 59380-98-2 CAPLUS
CN Acetamide, N-(4,5-dicyano-1H-imidazol-2-yl)-2-phenoxy- (CA INDEX NAME)



L5 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:112006 CAPLUS
DOCUMENT NUMBER: 82:112006
ORIGINAL REFERENCE NO.: 82:17899a,17902a
TITLE: Mononuclear heterocyclic rearrangements. VI. Conversion of 1,2,4-oxadiazoles into imidazoles
AUTHOR(S): Ruccia, M.; Vivona, N.; Cusmano, G.
CORPORATE SOURCE: Fac. Sci., Univ. Palermo, Palermo, Italy
SOURCE: Tetrahedron (1974), 30(21), 3859-64
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 82:112006

AB Condensation of aminooxadiazoles with β-oxo ketones or esters gave β-enamino ketones, which with NaOEt in DMF rearranged to imidazole derivs. E.g., I with (MeCO)2CH2 gave II, which with NaOEt in DMF gave III. Condensation of I with PhCOCH2CO2Et gave IV and V. V was in solution equilibrium with its tautomer VI.

IT 40483-42-9P 40483-44-1P 55729-98-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 40483-42-9 CAPLUS
CN Acetamide, N-(4-acetyl-5-methyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 40483-44-1 CAPLUS
CN Acetamide, N-(4-benzoyl-5-methyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 55729-98-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-(acetylamino)-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:405297 CAPLUS
DOCUMENT NUMBER: 79:5297
ORIGINAL REFERENCE NO.: 79:898h,899a
TITLE: Condensations with N,N'-hydrazinodicarboxamidine. 12. Proof of the 2-aminoimidazole structure by ring synthesis from cyanamide
AUTHOR(S): Kreutzberger, A.; Schuecker, R.
CORPORATE SOURCE: Inst. Pharm. Chem., Westfael. Wilhelms-Univ., Muenster, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1973), 306(3), 169-73
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German
AB The structure of the 2-aminoimidazoles [I, R = R1 = Me or RR1 = (CH2)4] formed by reduction of the corresponding 2,2'-azoimidazoles was supported by their synthesis from H2NCHR1COR and H2NCN.
IT 40639-97-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40639-97-2 CAPLUS
CN Acetamide, N-(4,5-dimethyl-1H-imidazol-2-yl)- (CA INDEX NAME)



L5 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:124496 CAPLUS
DOCUMENT NUMBER: 78:124496
ORIGINAL REFERENCE NO.: 78:20003a,20006a
TITLE: Condensations with hydrazine-N,N'-dicarboxamidines. 11. 2-Aminoimidazoles by reduction of 2,2'-azoimidazoles
AUTHOR(S): Kreutzberger, A.; Schuecker, R.
CORPORATE SOURCE: Inst. Pharm. Chem., Westfael. Wilhelms-Univ., Muenster, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1973), 306(2), 139-45
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German
AB The aminoimidazoles XNH2 (R = H or Me) and YNH2 were obtained by reduction of XN:NX or YN:Ny, resp., and were characterized by conversion into acyl derivs.
IT 40639-97-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40639-97-2 CAPLUS
CN Acetamide, N-(4,5-dimethyl-1H-imidazol-2-yl)- (CA INDEX NAME)



L5 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:97567 CAPLUS
DOCUMENT NUMBER: 78:97567
ORIGINAL REFERENCE NO.: 78:15659a,15662a
TITLE: Mononuclear heterocyclic rearrangements. V. 1,2,4-Oxadiazoles to imidazoles
AUTHOR(S): Ruccia, Michele; Vivona, Nicolo; Cusmano, Giuseppe
CORPORATE SOURCE: Fac. Sci., Univ. Palermo, Palermo, Italy
SOURCE: Tetrahedron Letters (1972), (49), 4959-60
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 78:97567
AB Condensing 3-amino-5-methyl-1,2,4-oxadiazole or the 5-Ph analog with MeCOCH2COMe or PhCOCH2COMe in refluxing PhMe containing p-MeC6H4SO3H for 8-10 hr gave the oxadiazole enamino ketones (I; R, R1 = Me, Ph). Rearrangement of I with 1 equivalent NaOEt in DMF at 110° for 3 hr gave 60-80% of the corresponding imidazoles (II). Acid hydrolysis of II gave 2-aminoimidazoles.
IT 40483-42-9P 40483-44-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acid hydrolysis of)
RN 40483-42-9 CAPLUS
CN Acetamide, N-(4-acetyl-5-methyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 40483-44-1 CAPLUS
CN Acetamide, N-(4-benzoyl-5-methyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1926:1672 CAPLUS
DOCUMENT NUMBER: 20:1672
ORIGINAL REFERENCE NO.: 20:193g-i

TITLE: 2-Amino-4,5-dimethylglyoxaline
AUTHOR(S): Burtles, Richard; Pyman, F. L.
SOURCE: Journal of the Chemical Society, Transactions (1925), 127, 2012-8
CODEN: JCHTA3; ISSN: 0368-1645
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB 2-p-Bromobenzeneazo-4,5-dimethylglyoxaline, light brown, m. 213-4° (all m. ps. are corrected); it seems to cause irritation of the skin and swelling of the eyelids; HCl salt, orange-yellow, decomps. 135°. Reduction by Sn and HCl gives 69% of 2-amino-4,5-dimethylglyoxaline-HCl, m. 389°; carbonate, with 1H2O, m. 144°; picrate, yellow, m. 245°. The amine reacts sluggishly with HNO2 in dilute or concentrated HCl or 25% AcOH, giving no crystalline products, but the solns. give deep colors on treatment with NaOH. It gives deeply colored solns. with Na2Fe(CN)6NO and aqueous NaOH or with AmNO2 and EtONa in EtOH. Ac derivative, m. 270°; after treating with HCl and NaNO2, it gives no color with β-C10H7ONa; it instantly decolorizes aqueous KMnO4. The NH2 derivative does not give a benzylidene derivative 2-p-Bromobenzeneazo-4(5)-methylglyoxaline (I), yellow, m. 225-6°. 5(4)-p-Bromobenzeneazo derivative, brown, m. 238°; HCl salt, yellow needles or yellow-red prisms, m. 188°. The yield of these 2 compds. is about 47 and 12%. The constitution of I was established by its reduction by Zn and AcOH to alacreatinine; this is also obtained with SnCl2 and HCl, together with about 10% of the 2-amino derivative, analyzed as the picrate, brownish yellow, m. 186-7°.

IT 40639-97-2P, Acetamide, N-(4,5-dimethyl-2-imidazolyl)-
RL: PREP (Preparation)
(preparation of)

RN 40639-97-2 CAPLUS

CN Acetamide, N-(4,5-dimethyl-1H-imidazol-2-yl)- (CA INDEX NAME)



=>
=> ....Testing the current file.... screen

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Please change to a suitable file and repeat your upload

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	97.00	275.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE -12.80 -12.80

FILE 'REGISTRY' ENTERED AT 11:40:27 ON 27 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 OCT 2008 HIGHEST RN 1065816-63-8
DICTIONARY FILE UPDATES: 24 OCT 2008 HIGHEST RN 1065816-63-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\STNEXP\Queries\10564010 str 3.str

L6 STRUCTURE UPLOADED

=> que L6

L7 QUE L6

=> d ;7
L7 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.
L7 QUE ABB=ON PLU=ON L6

7 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l7 sss full
FULL SEARCH INITIATED 11:40:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2382 TO ITERATE

100.0% PROCESSED 2382 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L8 1 SEA SSS FUL L6

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	453.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.80

FILE 'CAPLUS' ENTERED AT 11:40:57 ON 27 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Oct 2008 VOL 149 ISS 18
FILE LAST UPDATED: 26 Oct 2008 (20081026/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l8
L9           0 L8

=> d his

     (FILE 'HOME' ENTERED AT 11:30:00 ON 27 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 11:30:38 ON 27 OCT 2008
L1               STRUCTURE UPLOADED
L2               QUE L1
L3           22 S L2 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:31:05 ON 27 OCT 2008
L4           22 S L3
L5           16 S L4 AND PY<=2004

     FILE 'REGISTRY' ENTERED AT 11:40:27 ON 27 OCT 2008
L6               STRUCTURE UPLOADED
L7               QUE L6
L8            1 S L7 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:40:57 ON 27 OCT 2008
L9           0 S L8

=> s l7
SEARCH PROFILE NOT SUPPORTED FOR AUTOMATED SEARCH AND CROSSOVER
The search profile contains L-numbers or saved item names that include
chemical substance terms, chemical structures, or structure screen
sets. If you are in a single file environment using the CA file (CA,
HCA, ZCA, CAPLUS, HCAPLUS, ZCAPLUS), enter HELP FIRST at an arrow
prompt (=>) for information about the REGlstRY automated search and
crossover feature. REGlstRY supports the following search profiles:

Example 1:
   => ACT SCRSTR/Q
   L3              STR
   L4              SCR 2127
   L5              QUE  L3 NOT L4

   These searches are supported:
   S  L5/REG
   S  SCRSTR/Q/REG
   S  (L3 NOT L4)/REG
```

```
   These searches are not supported:
   S  L5
   S  SCRSTR/Q

Example 2:
   => ACT SCRSTR2/Q
   L6              STR
   L7              SCR 2127
   L8              QUE  L6
   L9              QUE  L7
   L10             QUE  L8 NOT L9

   This search is supported:
   S  (L6 NOT L7)/REG

   These searches are not supported:
   S  L10
   S  L10/REG
   S  SCRSTR2/Q
   S  SCRSTR2/Q/REG
   S  L8 NOT L9
   S  (L8 NOT L9)/REG

=> s l8
L10          0 L8

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.96     454.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -12.80

FILE 'REGISTRY' ENTERED AT 11:42:15 ON 27 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 OCT 2008  HIGHEST RN 1065816-63-8
DICTIONARY FILE UPDATES:  24 OCT 2008  HIGHEST RN 1065816-63-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html
```

```
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\Program Files\STNEXP\Queries\10564010 str 4.str

L11     STRUCTURE UPLOADED

=> que L11

L12  QUE L11

=> d l12
L12 HAS NO ANSWERS
L11              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L12              QUE  ABB=ON  PLU=ON  L11


=> s l12 sss full
FULL SEARCH INITIATED 11:42:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     5244 TO ITERATE

100.0% PROCESSED     5244 ITERATIONS                              126 ANSWERS
SEARCH TIME: 00.00.01

L13         126 SEA SSS FUL L11

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                    ENTRY    SESSION
FULL ESTIMATED COST                                178.36     633.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                  0.00     -12.80
```

```
FILE 'CAPLUS' ENTERED AT 11:42:56 ON 27 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 27 Oct 2008  VOL 149 ISS 18
FILE LAST UPDATED: 26 Oct 2008  (20081026/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l13
L14         44 L13

=> s l14 and py<=2004
      25113423 PY<=2004
L15         24 L14 AND PY<=2004

=> s l15 and 5-hydroxytryptamine
        6834776 5
          20870 HYDROXYTRYPTAMINE
             71 HYDROXYTRYPTAMINES
          20895 HYDROXYTRYPTAMINE
                (HYDROXYTRYPTAMINE OR HYDROXYTRYPTAMINES)
          20023 5-HYDROXYTRYPTAMINE
                (5(W)HYDROXYTRYPTAMINE)
L16          0 L15 AND 5-HYDROXYTRYPTAMINE

=> s l15 and 5HT
         3174 5HT
L17          0 L15 AND 5HT

=> s l15 1-24 ibib ab hitstr
MISSING OPERATOR L15 1-24
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l15 1-24 ibib ab hitstr
MISSING OPERATOR L15 1-24
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	9.92	643.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.80

FILE 'CAPLUS' ENTERED AT 11:44:31 ON 27 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Oct 2008 VOL 149 ISS 18
FILE LAST UPDATED: 26 Oct 2008 (20081026/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 11:30:00 ON 27 OCT 2008)

FILE 'REGISTRY' ENTERED AT 11:30:38 ON 27 OCT 2008
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 22 S L2 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:31:05 ON 27 OCT 2008
L4 22 S L3
L5 16 S L4 AND PY<=2004

FILE 'REGISTRY' ENTERED AT 11:40:27 ON 27 OCT 2008
L6 STRUCTURE UPLOADED
L7 QUE L6
L8 1 S L7 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:40:57 ON 27 OCT 2008
L9 0 S L8
L10 0 S L8

FILE 'REGISTRY' ENTERED AT 11:42:15 ON 27 OCT 2008
L11 STRUCTURE UPLOADED
L12 QUE L11
L13 126 S L12 SSS FULL

```
     FILE 'CAPLUS' ENTERED AT 11:42:56 ON 27 OCT 2008
L14            44 S L13
L15            24 S L14 AND PY<=2004
L16             0 S L15 AND 5-HYDROXYTRYPTAMINE
L17             0 S L15 AND 5HT

     FILE 'CAPLUS' ENTERED AT 11:44:31 ON 27 OCT 2008

=> s l15 1-24 ibib ab hitstr
MISSING OPERATOR L15 1-24
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l15 1-24 ibib ab hitstr

L15  ANSWER 1 OF 24  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:80450  CAPLUS
DOCUMENT NUMBER:          140:145835
TITLE:                    Preparation of dibenzofused
                          bicyclo[2.2.2]octane-derived amides as modulators of
                          the glucocorticoid receptor
INVENTOR(S):              Vaccaro, Wayne; Yang, Bingwei Vera; Kim, Soong-hoon;
                          Huynh, Tram; Tortolani, David R.; Leavitt, Kenneth J.;
                          Li, Wenying; Doweyko, Arthur M.; Chen, Xiao-tao;
                          Doweyko, Lidia
PATENT ASSIGNEE(S):       Bristol-Myers Squibb Company, USA; et al.
SOURCE:                   PCT Int. Appl., 265 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
     WO 2004009017        A2    20040129    WO 2003-US22300        20030717 <--
     WO 2004009017        A3    20040708
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003251970        A1    20040209    AU 2003-251970         20030717 <--
     US 20040132758       A1    20040708    US 2003-621909         20030717 <--
     US 6995181           B2    20060207
     EP 1534273           A2    20050601    EP 2003-765638         20030717
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006508042        T     20060309    JP 2004-523482         20030717
     NO 2005000074        A     20050309    NO 2005-74             20050106
     US 20050171136       A1    20050804    US 2005-85347          20050321
PRIORITY APPLN. INFO.:                      US 2002-396877P     P  20020718
                                            US 2003-621909      A1 20030717
                                            WO 2003-US22300     W  20030717

OTHER SOURCE(S):          MARPAT 140:145835
AB   Title compds. I [R-R4 = H, alk(en/yn)yl, alkoxy, aryl, etc.; Z =
```

carboxamido, alkylamino, etc.] are prepared For instance, 2-amino-4,5-dimethylthiazole is coupled to the acid derived from the cycloaddn. of methacrylic acid and anthracene (CH3CN, EDCI, Et3N, HOAt, 18 h) to give II. I are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders.

IT 650626-13-4 650626-17-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of glucocorticoid receptor)

RN 650626-13-4 CAPLUS
CN Acetamide, N-[5-(4-fluoro-1-naphthalenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 650626-17-8 CAPLUS
CN Acetamide, N-[5-(6-methoxy-1-naphthalenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



L15 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:80449 CAPLUS
DOCUMENT NUMBER: 140:157927
TITLE: Homology modeling of nuclear hormone receptor Site II and design of Site II ligands
INVENTOR(S): Doweyko, Arthur; Nadler, Steven G.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 276 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004009016	A2	20040129	WO 2003-US22299	20030717 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1575502	A2	20050921	EP 2003-765637	20030717
EP 1575502	A3	20051123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060223110	A1	20061005	US 2003-621807	20030717
PRIORITY APPLN. INFO.:			US 2002-396907P	P 20020718
			WO 2003-US22299	W 20030717

AB A binding site in nuclear hormone receptors is described and its structural coordinates are provided. The invention provides machine-readable data storage media comprising structure coordinates of Site II and computer systems comprising the machine-readable data storage media. The invention provides methods used in the design and identification of ligands of Site II and of modulators of nuclear hormone receptors. The invention provides ligands of Site II, modulators of NHRs, pharmaceutical compns. comprising modulators of NHRs, methods of modulating NHRs, and methods of treating diseases by administering modulators of an NHR. Also provided are methods of designing mutants, mutant NHRs, Site II binding assays, and models of Site II.

IT 650626-13-4P 650626-17-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(homol. modeling of nuclear hormone receptor Site II in ligand binding domain and design of Site II ligands)

RN 650626-13-4 CAPLUS
CN Acetamide, N-[5-(4-fluoro-1-naphthalenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 650626-17-8 CAPLUS
CN Acetamide, N-[5-(6-methoxy-1-naphthalenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



L15 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:41450 CAPLUS
DOCUMENT NUMBER: 140:87668
TITLE: Therapeutic imidazole compounds, and human cellular proteins casein kinase I α, δ, and ε as targets for medical intervention against hepatitis C virus infection
INVENTOR(S): Salassidis, Konstadinos; Kurtenbach, Alexander; Daub, Henrik; Obert, Sabine
PATENT ASSIGNEE(S): Axxima Pharmaceuticals A.-G., Germany; Greff, Zoltan; Keri, Gyoergy; Oerfi, Laszlo; Waczek, Frigyes
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005264	A2	20040115	WO 2003-EP7286	20030707 <--
WO 2004005264	A3	20040304		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003249977	A1	20040123	AU 2003-249977	20030707 <--
EP 1532118	A2	20050525	EP 2003-762649	20030707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050203155	A1	20050915	US 2005-30538	20050105

PRIORITY APPLN. INFO.: EP 2002-15096 A 20020705
WO 2003-EP7286 W 20030707

OTHER SOURCE(S): MARPAT 140:87668

AB The invention describes imidazole compds. which are particularly useful against Hepatitis C Virus infections and diseases associated therewith. Furthermore, the invention relates to the human cellular proteins casein kinase I α, δ, and ε as targets for medical intervention against Hepatitis C Virus (HCV) infections and diseases. In addition, the invention refers to a method for the identification of compds. which are useful for the prophylaxis and/or treatment of infections and diseases caused by Hepatitis C Virus, methods for treating Hepatitis C Virus infections and diseases, as well as pharmaceutical comps. useful

for the prophylaxis and/or treatment of Hepatitis C Virus infections and diseases. Moreover, the invention discloses antibodies, oligonucleotides, and specific compds. which are effective for the detection, prophylaxis and/or treatment of infections and diseases caused by Hepatitis C Virus. In addition, the invention describes solid supports useful for the identification of compds. suitable for preventing and/or treating infections and diseases caused by Hepatitis C Virus.

IT 643750-56-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic imidazole compds., and human cellular casein kinase I α, δ, and ε as targets for medical intervention against hepatitis C virus infection)

RN 643750-56-5 CAPLUS

CN Acetamide, N-[4-(4-chlorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



L15 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:511143 CAPLUS

DOCUMENT NUMBER: 139:85387

TITLE: Preparation of heterocyclic substituted phenylsulfonamides as broad-spectrum HIV protease inhibitors

INVENTOR(S): Vendeville, Sandrine Marie Helene; Verschueren, Wim Gaston; Tahri, Abdellah; Moors, Samuel Leo Christiaan; Erra Sola, Montserrat

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053435	A1	20030703	WO 2002-EP14839	20021220 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2470964	A1	20030703	CA 2002-2470964	20021220 <--

AU 2002361235	A1	20030709	AU 2002-361235	20021220	<--
AU 2002361235	B2	20080724			
EP 1463502	A1	20041006	EP 2002-796754	20021220	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002015260	A	20041207	BR 2002-15260	20021220	<--
JP 2005513102	T	20050512	JP 2003-554192	20021220	
CN 1620292	A	20050525	CN 2002-828166	20021220	
HU 2005000164	A2	20050530	HU 2005-164	20021220	
MX 2004PA06201	A	20041206	MX 2004-PA6201	20040621	<--
NZ 533665	A	20051028	NZ 2004-533665	20040621	
IN 2004DN01777	A	20050401	IN 2004-DN1777	20040622	
NO 2004003114	A	20040920	NO 2004-3114	20040720	<--
ZA 2004005784	A	20050831	ZA 2004-5784	20040720	
US 20050222215	A1	20051006	US 2005-499221	20050412	
PRIORITY APPLN. INFO.:			EP 2001-205115 A	20011221	
			WO 2002-EP14839 W	20021220	

OTHER SOURCE(S): MARPAT 139:85387

AB R1LN(R2)CHR3CH(OH)CH2N(R4)SO2C6H4R5 [R1 = H, alkyl, alkenyl, aralkyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, heterocyclylalkyl, (un)substituted CH2CH2NH2; L = CO, O2C, (un)substituted NHCO, oxaalkylcarbonyl, aminoalkylcarbonyl, SO2, O3S, (un)substituted NHSO2; R2 = H, alkyl; R3 = alkyl, aryl, cycloalkyl, cycloalkylalkyl, aralkyl; R4 = H, (un)substituted CO2H, CONH2, cycloalkyl, alkenyl, alkynyl, alkyl; R5 = (un)substituted heteroaryl] were prepared for use as broad-spectrum HIV protease inhibitors. Thus, (1S,2R)-Me3CO2CNHCH(CH2Ph)CH(OH)CH2NHCH2CHMe2 was treated with 4-NCC6H4SO2Cl to give (1S,2R)-Me3CO2CNHCH(CH2Ph)CH(OH)CH2N(CH2CHMe2)SO2C6H4CN-4 which was deblocked and treated with the hexahydrofurofuranyloxycarbonyloxypyrrolidinedione to give the carbamate I [R6 = CN]. Treatment of I [R6 = CN] with NH2OH.HCl gave I [R6 = C(NH2):NOH] which was cyclized with 2-furoyl chloride to give I [R6 = 5-(2-furyl)-1,2,4-oxadiazol-3-yl] which had pEC50 = 8.4 for inhibition of HIV-1.

IT 553644-43-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic substituted phenylsulfonamides as broad-spectrum HIV protease inhibitors)

RN 553644-43-2 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[[4-[2-(acetylamino)-1H-imidazol-4-yl]phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 553645-06-0P 553645-07-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic substituted phenylsulfonamides as broad-spectrum HIV protease inhibitors)
RN 553645-06-0 CAPLUS
CN Acetamide, N-[5-[4-[[[(2R,3S)-3-[bis(phenylmethyl)amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenyl]-1H-imidazol-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 553645-07-1 CAPLUS
CN Acetamide, N-[5-[4-[[[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]phenyl]-1H-imidazol-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:58069 CAPLUS
DOCUMENT NUMBER: 138:122639
TITLE: Preparation of thiazols and related compounds as telomerase inhibitors
INVENTOR(S): Priepke, Henning; Kauffmann-Hefner, Iris; Hauel, Norbert; Damm, Klaus; Schnapp, Andreas
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     WO 2003006443         A2    20030123    WO 2002-EP7558          20020706 <--
     WO 2003006443         A3    20030501
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     DE 10133665           A1    20030130    DE 2001-10133665        20010711 <--
     AU 2002328323         A1    20030129    AU 2002-328323          20020706 <--
     US 20030055263        A1    20030320    US 2002-192456          20020710 <--
PRIORITY APPLN. INFO.:                       DE 2001-10133665     A  20010711
                                             US 2001-307449P      P  20010724
                                             WO 2002-EP7558       W  20020706

OTHER SOURCE(S):         MARPAT 138:122639
AB   Title compds. R1-A-B-R2 (I) [ R1 = (un)substituted Ph, phenylalkyl,
     phenylalkenyl, etc.; A = (un)substituted phenylalkyl; B = HN, NHCO, CONH,
     etc.; R2 = CO2, (un)substituted cycloalkyl, cycloalkenyl, etc.] and their
     pharmaceutically acceptable salts were prepared  For example, coupling of
     thiazol II and phthalic anhydride afforded claimed benzoic acid III in 30%
     yield.  In telomerase inhibition studies, 3-specific examples of I
     exhibited IC50 values ranging from < 1 - < 5 μM, e.g., IC50 value of
     compound III was < 5 μM.  Compds. I are claimed useful as telomerase
     inhibitors.
IT   160072-53-7P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (intermediate; preparation of thiazols and related compds. as telomerase
        inhibitors)
RN   160072-53-7  CAPLUS
CN   Acetamide, N-[5-(2-naphthalenyl)-1H-imidazol-2-yl]-  (CA INDEX NAME)
```




```
L15  ANSWER 6 OF 24  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2002:855867  CAPLUS
DOCUMENT NUMBER:         139:214346
TITLE:                   Product class 3: imidazoles
AUTHOR(S):               Grimmett, M. R.
CORPORATE SOURCE:        Organic Chemistry, Dept. of Chemistry, University of
                         Otago, Dunedin, N. Z.
SOURCE:                  Science of Synthesis (2002), 12, 325-528
                         CODEN: SSCYJ9
PUBLISHER:               Georg Thieme Verlag
DOCUMENT TYPE:           Journal; General Review
LANGUAGE:                English
AB   A review.  Methods for preparing imidazoles are reviewed including
     cyclization, ring transformations, aromatization and modification of
     substituents on existing imidazoles.
IT   160041-64-5P 160072-51-5P 160072-52-6P
```

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazoles via cyclization, ring transformation, aromatization and substituent modifications)

RN 160041-64-5 CAPLUS
CN Acetamide, N-(5-phenyl-1H-imidazol-2-yl)- (CA INDEX NAME)



RN 160072-51-5 CAPLUS
CN Acetamide, N-(4-methyl-5-phenyl-1H-imidazol-2-yl)- (CA INDEX NAME)



RN 160072-52-6 CAPLUS
CN Acetamide, N-(4,5-diphenyl-1H-imidazol-2-yl)- (CA INDEX NAME)



REFERENCE COUNT: 823 THERE ARE 823 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:773670 CAPLUS
DOCUMENT NUMBER: 137:279200
TITLE: Preparation of novel benzotriazoles as anti-inflammatory compounds
INVENTOR(S): Dombroski, Mark Anthony; Laird, Ellen Ruth; Letavic, Michael Anthony; McClure, Kim Francis
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 69 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1247810	A1	20021009	EP 2002-252153	20020326 <--
EP 1247810	B1	20050907		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

AT 304009	T	20050915	AT 2002-252153	20020326
ES 2247271	T3	20060301	ES 2002-252153	20020326
CA 2379903	A1	20021004	CA 2002-2379903	20020402 <--
CA 2379903	C	20060801		
JP 2002308872	A	20021023	JP 2002-102969	20020404 <--
JP 3832646	B2	20061011		
US 20030078432	A1	20030424	US 2002-115952	20020404 <--
US 6664395	B2	20031216		
BR 2002001087	A	20030527	BR 2002-1087	20020404 <--
MX 2002PA03454	A	20040716	MX 2002-PA3454	20020404 <--

PRIORITY APPLN. INFO.: US 2001-281331P P 20010404
OTHER SOURCE(S): MARPAT 137:279200

AB The title compds. [I; Het = (un)substituted pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, Ph, etc.; s = 0-5] which are potent inhibitors of MAP kinases, preferably p38 kinase (no data given), and are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders, were prepared Thus, treating a solution of 3-isopropyl-3H-benzotriazole-5-carbaldehydein THF with concentrate NH4OH followed by addition of piperazine and isocyanide II afforded III.

IT 467234-98-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel benzotriazoles as antiinflammatory agents)

RN 467234-98-6 CAPLUS
CN Acetamide, N-[5-(1-methyl-1H-benzotriazol-6-yl)-4-(3-methylphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:716272 CAPLUS
DOCUMENT NUMBER: 137:232656
TITLE: Preparation of 5-(phenylheteroaryl)-1,3-dihydro-2-benzimidazolone MAP kinase inhibitors as anti-inflammatory agents
INVENTOR(S): Dombroski, Mark Anthony; Letavic, Michael Anthony; McClure, Kim Francis
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 272 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002072576	A1	20020919	WO 2002-IB334	20020130	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2440211	A1	20020919	CA 2002-2440211	20020130	<--
AU 2002226639	A1	20020924	AU 2002-226639	20020130	<--
EP 1370557	A1	20031217	EP 2002-716257	20020130	<--
EP 1370557	B1	20051116			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2002007957	A	20040225	BR 2002-7957	20020130	<--
JP 2004526727	T	20040902	JP 2002-571492	20020130	<--
AT 309997	T	20051215	AT 2002-716257	20020130	
ES 2251582	T3	20060501	ES 2002-716257	20020130	
US 20030092749	A1	20030515	US 2002-94717	20020311	<--
US 7056918	B2	20060606			
MX 2003PA08142	A	20031212	MX 2003-PA8142	20030909	<--
PRIORITY APPLN. INFO.:			US 2001-274791P	P 20010309	
			WO 2002-IB334	W 20020130	

OTHER SOURCE(S): CASREACT 137:232656; MARPAT 137:232656

AB Title compds. I [wherein Het = (un)substituted pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, Ph, heteroaryl, or heterocyclyl; R3 = independently halo, (perhalo)alkyl, (perhalo)cycloalkyl, alkenyl, alkynyl, heterocyclyl(oxy), Ph, OH, (perhalo)alkoxy, OPh, alkylthio, alkyl(amino)sulfonyl, alkylsulfamoyl, carbamoyl, acyl, carboxy, etc.; n = 0-5] were prepared as potent inhibitors of MAP kinases, preferably p38 kinase. For example, (3R)-(-)-1-benzyl-3-aminopyrrolidine was condensed with 1,3-diethyl-2-oxo-2,3-dihydro-1H-benzimidazole-5-carbaldehyde in the presence of MgSO4 in CH2Cl2. Addition of [(4-methylphenylsulfonyl)(m-tolyl)methyl]isocyanide to the 5-(benzylpyrrolidinyliminomethyl)benzimidazolone using DMF and MP-carbonate gave the 5-(m-tolyl)imidazolyl derivative Treatment with Pd/C and HCl in MeOH afforded (R)-II•HCl. All of the compds. of the invention that were tested had an IC50 < 10 μM in TNFα and MAPKAP in vitro assays and an ED50 < mg/kg in an in vivo TNFα assay. I are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion of ischemia in stroke or heart attack, autoimmune diseases, and other disorders (no data).

IT 459184-45-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(anti-inflammatory agent; preparation of (phenylheteroaryl)benzimidazolone MAP kinase inhibitors as anti-inflammatory agents)

RN 459184-45-3 CAPLUS

CN Acetamide, N-[5-(3-chlorophenyl)-4-(1-cyclopentyl-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-5-yl)-1H-imidazol-2-yl]- (CA INDEX NAME)



IT 459183-44-9P, N-[5-(1-Isobutyl-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)-4-(m-tolyl)-1H-imidazol-2-yl]acetamide
459183-59-6P 459183-75-6P 459183-83-6P
459184-04-4P 459184-13-5P 459184-21-5P
459184-53-3P 459184-69-1P 459184-85-1P
459184-93-1P 459185-01-4P 459185-09-2P
459185-17-2P 459185-25-2P 459185-33-2P
459185-41-2P 459185-49-0P 459185-57-0P
459185-88-7P 459185-96-7P 459186-03-9P
459186-17-5P 459186-24-4P 459186-55-1P
459187-09-8P 459187-16-7P 459187-24-7P
459187-39-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-inflammatory agent; preparation of (phenylheteroaryl)benzimidazolone MAP kinase inhibitors as anti-inflammatory agents)

RN 459183-44-9 CAPLUS
CN Acetamide, N-[5-[2,3-dihydro-3-methyl-1-(2-methylpropyl)-2-oxo-1H-benzimidazol-5-yl]-4-(3-methylphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459183-59-6 CAPLUS
CN Acetamide, N-[5-(1,3-diethyl-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-4-(3-methylphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459183-75-6 CAPLUS
CN Acetamide, N-[5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-4-(4-fluorophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459183-83-6 CAPLUS
CN Acetamide, N-[5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-4-phenyl-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459184-04-4 CAPLUS
CN Acetamide, N-[5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-4-(3-methylphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459184-13-5 CAPLUS
CN Acetamide, N-[5-(1,3-diethyl-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-4-(4-fluorophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459184-21-5 CAPLUS
CN Acetamide, N-[5-(1,3-diethyl-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-4-phenyl-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459184-53-3 CAPLUS
CN Acetamide, N-[5-(1-cyclopentyl-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-5-yl)-4-(3-methylphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459184-69-1 CAPLUS
CN Acetamide, N-[5-[1-(cyclopropylmethyl)-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-5-yl]-4-(3-methylphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459184-85-1 CAPLUS
CN Acetamide, N-[5-[2,3-dihydro-3-methyl-1-(2-methylpropyl)-2-oxo-1H-benzimidazol-5-yl]-4-(4-fluorophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459184-93-1 CAPLUS
CN Acetamide, N-[5-[2,3-dihydro-3-methyl-1-(1-methylethyl)-2-oxo-1H-benzimidazol-5-yl]-4-(4-fluorophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459185-01-4 CAPLUS
CN Acetamide, N-[5-[2,3-dihydro-3-methyl-1-(1-methylethyl)-2-oxo-1H-benzimidazol-5-yl]-4-(3-methylphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459185-09-2 CAPLUS
CN Acetamide, N-[5-[2,3-dihydro-3-methyl-1-(2-methylpropyl)-2-oxo-1H-benzimidazol-5-yl]-4-(4-fluorophenyl)-1H-imidazol-2-yl]-2-methoxy- (CA INDEX NAME)



RN 459185-17-2 CAPLUS
CN Propanamide, N-[5-[2,3-dihydro-3-methyl-1-(1-methylethyl)-2-oxo-1H-benzimidazol-5-yl]-4-(4-fluorophenyl)-1H-imidazol-2-yl]-2-methyl- (CA INDEX NAME)



RN 459185-25-2 CAPLUS
CN Propanamide, N-[5-[2,3-dihydro-3-methyl-1-(2-methylpropyl)-2-oxo-1H-benzimidazol-5-yl]-4-(3-methylphenyl)-1H-imidazol-2-yl]-2-methyl- (CA INDEX NAME)



RN 459185-33-2 CAPLUS
CN Propanamide, N-[5-[2,3-dihydro-3-methyl-1-(2-methylpropyl)-2-oxo-1H-benzimidazol-5-yl]-4-(4-fluorophenyl)-1H-imidazol-2-yl]-2-methyl- (CA INDEX NAME)



RN 459185-41-2 CAPLUS
CN Butanamide, N-[5-[2,3-dihydro-3-methyl-1-(2-methylpropyl)-2-oxo-1H-benzimidazol-5-yl]-4-(3-methylphenyl)-1H-imidazol-2-yl]-3,3-dimethyl- (CA INDEX NAME)



RN 459185-49-0 CAPLUS
CN Butanamide, N-[5-[2,3-dihydro-3-methyl-1-(2-methylpropyl)-2-oxo-1H-benzimidazol-5-yl]-4-(4-fluorophenyl)-1H-imidazol-2-yl]-3,3-dimethyl- (CA INDEX NAME)



RN 459185-57-0 CAPLUS
CN Butanamide, N-[5-[2,3-dihydro-3-methyl-1-(2-methylpropyl)-2-oxo-1H-benzimidazol-5-yl]-4-(4-fluorophenyl)-1H-imidazol-2-yl]-3-methyl- (CA INDEX NAME)



RN 459185-88-7 CAPLUS
CN Acetamide, N-[5-[2,3-dihydro-3-methyl-1-(1-methylethyl)-2-oxo-1H-benzimidazol-5-yl]-4-(3-methylphenyl)-1H-imidazol-2-yl]-2-methoxy- (CA INDEX NAME)



RN 459185-96-7 CAPLUS
CN Acetamide, N-[5-[2,3-dihydro-3-methyl-1-(2-methylpropyl)-2-oxo-1H-benzimidazol-5-yl]-4-(3-methylphenyl)-1H-imidazol-2-yl]-2-methoxy- (CA INDEX NAME)



RN 459186-03-9 CAPLUS
CN Butanamide, N-[5-[2,3-dihydro-3-methyl-1-(2-methylpropyl)-2-oxo-1H-benzimidazol-5-yl]-4-(3-methylphenyl)-1H-imidazol-2-yl]-3-methyl- (CA INDEX NAME)



RN 459186-17-5 CAPLUS
CN Propanamide, N-[5-[2,3-dihydro-3-methyl-1-(2-methylpropyl)-2-oxo-1H-benzimidazol-5-yl]-4-(3-methylphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459186-24-4 CAPLUS
CN Acetamide, N-[5-[2,3-dihydro-3-methyl-2-oxo-1-(tetrahydro-3-furanyl)-1H-benzimidazol-5-yl]-4-(4-fluorophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459186-55-1 CAPLUS
CN Acetamide, N-[5-[2,3-dihydro-3-methyl-2-oxo-1-(tetrahydro-3-furanyl)-1H-benzimidazol-5-yl]-4-(3-methylphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459187-09-8 CAPLUS
CN Acetamide, N-[4-[2,3-dihydro-3-methyl-1-(1-methylethyl)-2-oxo-1H-benzimidazol-5-yl]-5-(3-fluorophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459187-16-7 CAPLUS
CN Acetamide, N-[4-[2,3-dihydro-3-methyl-1-(1-methylethyl)-2-oxo-1H-benzimidazol-5-yl]-5-(2-fluorophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459187-24-7 CAPLUS
CN Acetamide, N-[4-(4-chlorophenyl)-5-[2,3-dihydro-3-methyl-1-(1-methylethyl)-2-oxo-1H-benzimidazol-5-yl]-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 459187-39-4 CAPLUS
CN Acetamide, N-[5-[2,3-dihydro-3-methyl-1-(1-methylethyl)-2-oxo-1H-benzimidazol-5-yl]-4-phenyl-1H-imidazol-2-yl]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:283949 CAPLUS
DOCUMENT NUMBER: 134:311218
TITLE: Synthesis and use of heterocyclic sodium/proton exchange inhibitors
INVENTOR(S): Ahmad, Saleem; Wu, Shung C.; O'Neil, Steven V.; Ngu, Khehyong; Atwal, Karnail S.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 221 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027107	A2	20010419	WO 2000-US27461	20001002 <--
WO 2001027107	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6887870	B1	20050503	US 2000-669298	20000925
CA 2388813	A1	20010419	CA 2000-2388813	20001002 <--

EP 1224183	A2	20020724	EP 2000-968723	20001002	<--
EP 1224183	B1	20051228			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
BR 2000014725	A	20030617	BR 2000-14725	20001002	<--
HU 2003000195	A2	20030728	HU 2003-195	20001002	<--
HU 2003000195	A3	20030929			
JP 2003527331	T	20030916	JP 2001-530325	20001002	<--
NZ 517668	A	20040924	NZ 2000-517668	20001002	<--
AT 314364	T	20060115	AT 2000-968723	20001002	
ES 2254236	T3	20060616	ES 2000-968723	20001002	
IN 2002MN00354	A	20050318	IN 2002-MN354	20020322	
ZA 2002002479	A	20040727	ZA 2002-2479	20020327	<--
MX 2002PA03626	A	20030922	MX 2002-PA3626	20020410	<--
NO 2002001717	A	20020610	NO 2002-1717	20020411	<--
US 2005013716	A1	20050623	US 2005-46993	20050131	
US 7326705	B2	20080205			

PRIORITY APPLN. INFO.:	US 1999-158755P	P	19991012
	US 2000-669298	A3	20000925
	WO 2000-US27461	W	20001002

OTHER SOURCE(S): MARPAT 134:311218

AB Compds. of formula I [wherein; n is 1-5; X is N or CR5, where R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group; R1 is H, alk(en)(yn)yl, alk(enyl)(ynyl)oxy, (aryl or alkyl)3Si, cycloalk(en)yl, (aryl)amino, aryl(alkyl), cycloheteroaryl, etc.; R2, R3 and R4 are any of the groups set out for R1 and optionally substituted with 1 to 5 substituents which may be the same or different and when X is N, R1 is preferably aryl or heteroaryl] are claimed. Several hundred examples are disclosed. Synthesis of II proceeds via cyclopropanation of the cinnamate derived from the olefination between 3,5-dichlorobenzaldehyde and t-butyldiethylphosphonoacetate. The intermediate tert-Bu ester is converted to the corresponding α-chloroketone and reacted with acetyl guanidine to provide II in a total of 5 steps. Compds. I are said to be sodium/proton exchange inhibitors (NHE). Pharmaceutical combinations are claimed using I and certain antihypertensive agents, β-adrenergic agonists, hypolipidemic agents, antidiabetic agents, antiobesity agents, etc. Compds. I are useful as antianginal and cardioprotective agents and provide a method for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia.

IT 335061-48-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and use of heterocyclic sodium/proton exchange inhibitors)

RN 335061-48-8 CAPLUS

CN Acetamide, N-[4-[(1R,3R)-3-(3-chlorophenyl)-2,2-dimethylcyclopropyl]-5-phenyl-1H-imidazol-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L15 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:98527 CAPLUS
DOCUMENT NUMBER: 132:137388
TITLE: Preparation of N-imidazolylalkyl-2-imidazoleamines as histamine H3 receptor ligands
INVENTOR(S): Jegham, Samir; Saady, Mourad; Yaiche, Philippe; Horter, Laurence
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006552	A1	20000210	WO 1999-FR1824	19990726 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2781798	A1	20000204	FR 1998-9602	19980728 <--
FR 2781798	B1	20000908		
AU 9949166	A1	20000221	AU 1999-49166	19990726 <--
PRIORITY APPLN. INFO.:			FR 1998-9602 A	19980728
			WO 1999-FR1824 W	19990726

OTHER SOURCE(S): MARPAT 132:137388
AB RZNH(CH2)mR1 (R1 = 1H-imidazole-4-yl)[I; R = (un)substituted Ph; Z = (un)substituted 1H-imidazole-5,2-diyl; m = 2-4] were prepared Thus, PhCH(OH)COPh was cyclocondensed with urea and the chlorinated product aminated by H2CH2Ph to give, after deprotection, 4,5-diphenyl-1H-imidazole-2-amine which was amidated by 1H-imidazole-4-propanoic acid and the product reduced to give I (R = Ph, Z = 3-phenyl-1H-imidazole-5,2-diyl, m = 3). Data for biol. activity of I were given.
IT 256657-13-3P 256657-15-5P 256657-16-6P
256657-18-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-imidazolylalkyl-2-imidazoleamines as histamine H3 receptor ligands)
RN 256657-13-3 CAPLUS
CN 1H-Imidazole-5-propanamide, N-(4,5-diphenyl-1H-imidazol-2-yl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 256657-15-5 CAPLUS
CN 1H-Imidazole-5-propanamide, N-[5-(4-fluorophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 256657-16-6 CAPLUS
CN 1H-Imidazole-5-propanamide, N-[5-(4-chloro-3-methylphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 256657-18-8 CAPLUS
CN 1H-Imidazole-5-butanamide, N-(5-phenyl-1H-imidazol-2-yl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:723017 CAPLUS
DOCUMENT NUMBER: 131:337034
TITLE: Preparation of 1-naphthylsulfonyl-4-heteroarylbenzoylpiperazines and analogs as Factor Xa inhibitors
INVENTOR(S): Nowak, Thorsten; Preston, John; Rayner, John Wall; Smithers, Michael James; Stocker, Andrew
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9957099	A1	19991111	WO 1999-GB1312	19990427 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9936207	A	19991123	AU 1999-36207	19990427 <--
EP 1082303	A1	20010314	EP 1999-918179	19990427 <--
EP 1082303	B1	20050126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 287874	T	20050215	AT 1999-918179	19990427
US 6395731	B1	20020528	US 2000-674563	20001220 <--
PRIORITY APPLN. INFO.:			GB 1998-9349 A	19980502
			WO 1999-GB1312 W	19990427

OTHER SOURCE(S): MARPAT 131:337034

AB Title compds. (I) [where A = 5- or 6-membered monocyclic heteroaryl (un)substituted by 1-3 halo, oxo, CO2H, CF3, CN, NH2, OH, NO2, (amino)alkyl, alkoxy(carbonyl), and/or (di)alkylamino; Y = (un)substituted phenylene; Z = (un)substituted piperidine-4,1-diyl or piperazine-1,4-diyl; D and D1 = independently H, alkyl, alkenyl, alkynyl, oxo, or OH; E = F, Cl, or Br] were prepared as antithrombotics and anticoagulants. Thus, 4-(4-imidazolyl)benzoic acid HCl (2-step preparation given) was amidated with 1-(6-chloronaphth-2-ylsulfonyl)piperazine to yield the title imidazolylbenzoylpiperazine (II). The IC50 values of invention compds. ranged from 0.001 to 0.1 μM for Factor Xa inhibition and were > 40 μM for thrombin inhibition (no individual data given). Data for anticoagulant activity of I in conventional prothrombin time tests were given.

IT 249887-81-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 1-naphthylsulfonyl-4-heteroarylbenzoylpiperazines and analogs as Factor Xa inhibitors for treatment of thrombosis mediated diseases and coagulation disorders)

RN 249887-81-8 CAPLUS
CN Acetamide, N-[5-(4-cyanophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:659664 CAPLUS

DOCUMENT NUMBER: 131:271809
TITLE: Preparation of 3-(α-heteroarylaminobenzylidene)-2-indolinones as Cyclin dependent kinase inhibitors
INVENTOR(S): Grell, Wolfgang; Walter, Rainer; Heckel, Armin; Himmelsbach, Frank; Wittneben, Helmut; van Meel, Jakobus; Redemann, Norbert; Haigh, Robert
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: Ger. Offen., 64 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19815020	A1	19991007	DE 1998-19815020	19980403 <--
US 6043254	A	20000328	US 1999-277063	19990326 <--
WO 9951590	A1	19991014	WO 1999-EP2186	19990330 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9937034	A	19991025	AU 1999-37034	19990330 <--

PRIORITY APPLN. INFO.:
DE 1998-19815020 A 19980403
US 1998-86733P P 19980526
WO 1999-EP2186 W 19990330

OTHER SOURCE(S): MARPAT 131:271809

AB Title compds. [I; R = H; R1 = H, halo, NO2, (alkanoyl)amino, etc.; R2 = (un)substituted Ph; R4 = NHR3; R3 = heteroannelated Ph, heteroarylalk(en)ylphenyl, etc.] were prepared Thus,2-indolinone was N-acetylated and the product condensed with PhC(OEt)3 to give I (R1 = H, R2 = Ph)(II; R = Ac, R4 = OEt) which was condensed with 5-aminoindole to give II (R = H, R4 = 5-indolylamino). Data for biol. activity of I were given.

IT 245546-35-4P 245546-36-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(α-heteroarylaminobenzylidene)-2-indolinones as cyclin dependent kinase inhibitors)

RN 245546-35-4 CAPLUS

CN Acetamide, N-[5-[4-[[(Z)-(1,2-dihydro-5-nitro-2-oxo-3H-indol-3-ylidene)phenylmethyl]amino]phenyl]-1H-imidazol-2-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 245546-36-5 CAPLUS
CN Acetamide, N-[5-[4-[[(Z)-(1,2-dihydro-5-nitro-2-oxo-3H-indol-3-ylidene)phenylmethyl]amino]phenyl]-4-methyl-1H-imidazol-2-yl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 96139-64-9P 96139-70-7P 160072-51-5P
245546-86-5P 245546-87-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(α-heteroarylaminobenzylidene)-2-indolinones as cyclin dependent kinase inhibitors)
RN 96139-64-9 CAPLUS
CN Acetamide, N-[5-(4-aminophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 96139-70-7 CAPLUS
CN Acetamide, N-[5-(4-nitrophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 160072-51-5 CAPLUS
CN Acetamide, N-(4-methyl-5-phenyl-1H-imidazol-2-yl)- (CA INDEX NAME)



RN 245546-86-5 CAPLUS
CN Acetamide, N-[4-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 245546-87-6 CAPLUS
CN Acetamide, N-[5-(4-aminophenyl)-4-methyl-1H-imidazol-2-yl]- (CA INDEX NAME)



L15 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:109589 CAPLUS
DOCUMENT NUMBER: 130:237506
TITLE: Synthesis of novel 4,5-diphenylthiazole derivatives as potential acyl-CoA : cholesterol O-acyltransferase inhibitors
AUTHOR(S): Romeo, G.; Salerno, L.; Milla, P.; Siracusa, M.; Cattel, L.; Russo, Filippo
CORPORATE SOURCE: Dip. Scienze Farmaceutiche, Univ. Catania, Catania, I-95125, Italy
SOURCE: Pharmazie (1999), 54(1), 19-23
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 130:237506
AB Several N-(4,5-diphenylthiazol-2-yl)-N'-aryl- or -alkyl-(thio)ureas and N-(4,5-diphenylthiazol-2-yl)alkanamides were prepared as potential acyl-CoA : cholesterol O-acyltransferase (ACAT) inhibitors. Synthesis was accomplished by reaction of 2-amino-4,5-diphenylthiazole with suitable isocyanates, isothiocyanates, or acyl chlorides. Some analogs without a 5-Ph substituent or both the Ph groups in 4- and 5-position of the thiazole ring were also prepared Moreover, some bio-isosteres of the title

compds. in which the thiazole ring was replaced by an imidazole were synthesized starting from 2-amino-4,5-diphenyl-1H-imidazole. The ability of synthesized compds. to inhibit ACAT was evaluated in vitro by measuring the formation of cholesteryl[14C]oleate from cholesterol and [1-14C]oleoyl-CoA in rat liver microsomes. Among the tested compds., only some thiazole ureas were able to inhibit ACAT in a reasonable degree. N-(4,5-diphenylthiazol-2-yl)-N'-[2,6-bis(2-methylethyl)phenyl]urea and N-(4,5-diphenylthiazol-2-yl)-N'-butylurea were the most active compds. in the series showing IC50 values in the low micromolar range.

IT 221389-49-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of phenylthiazoles cholesterol O-acyltransferase inhibitors)

RN 221389-49-7 CAPLUS

CN Hexanamide, N-(4,5-diphenyl-1H-imidazol-2-yl)- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:217660 CAPLUS
DOCUMENT NUMBER: 128:277027
ORIGINAL REFERENCE NO.: 128:54715a,54718a
TITLE: Silver halide photographic material and its processing method providing superior silver tone
INVENTOR(S): Yamashita, Hiroshi
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10090821	A	19980410	JP 1996-244931	19960917 <--
PRIORITY APPLN. INFO.:			JP 1996-244931	19960917

OTHER SOURCE(S): MARPAT 128:277027

AB The material comprises ≥1 Ag halide emulsion layer on ≥1 side of a support and ≥1 hydrophilic colloid layer containing a leuco dye producing blue color in reaction with an oxidized developer and a branched cyclodextrin and/or a cyclodextrin polymer. The material is processed with a developer containing ascorbic acid-type compound Q1C(:Q3)CR1:CR2Q2 (I; R1, R2 = OH, amino, acylamino, alkylsulfonylamino, arylsulfonylamino, alkoxycarbonylamino, mercapto, alkylthio; Q1, Q2 = OH, CO2H, alkoxy, hydroxyalkyl, carboxyalkyl, sulfo, sulfoalkyl, amino, aminoalkyl, alkyl, aryl, non-metallic atoms required to form a 5- to 8-membered ring with a carbon substituted with R1, R2, and Q3; Q3 = O, NR3; R3 = H, OH, alkyl, acyl, hydroxyalkyl, sulfoalkyl, carboxyalkyl) and an auxiliary developer. Alternatively, the material without the

cyclodextrin-based component is processed with a developer containing I, an auxiliary developer, a branched cyclodextrin and/or a cyclodextrin polymer. The material processed by the method shows superior silver tone and stable photog. properties even in running processing with lower replenishment of an ascorbic acid and its derivative instead of a hydroquinone.

IT 205577-10-2
RL: MOA (Modifier or additive use); USES (Uses)
(leuco dye; silver halide emulsion containing blue-color-forming leuco dye reactive to oxidized photog. developer)

RN 205577-10-2 CAPLUS

CN Propanamide, N-[4-[2-(acetylamino)phenyl]-5-[[4-(diethylamino)-2-methylphenyl]amino]-1H-imidazol-2-yl]-2,2-dimethyl- (CA INDEX NAME)



L15 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:472632 CAPLUS
DOCUMENT NUMBER: 125:127626
ORIGINAL REFERENCE NO.: 125:23665a,23668a
TITLE: Silver halide photographic material containing anilinoimidazole to develop dye image with high spectral absorption
INVENTOR(S): Ookawa, Atsuhiro; Sakai, Minoru
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08122960	A	19960517	JP 1994-263792	19941027 <--
JP 3505240	B2	20040308		
PRIORITY APPLN. INFO.:			JP 1994-263792	19941027

AB The claimed photog. material having, on a support, ≥1 light-sensitive Ag halide emulsion layer(s) contains an imidazole compound substituted by an anilino group (H atom on NH group is unsubstituted) at 2- or 4-site. Preferable imidazole derivative is represented by the formula I (R1-4 = H, nonmetal substituent; X = OH, NR5R6; R5, R6 = H, alkyl, aryl, heterocyclic group; A, B = nonmetal substituent). The compound is a leuco dye with high dye developability and the developed dye has a high spectral absorbance.

IT 179421-93-3P
RL: DEV (Device component use); PNU (Preparation, unclassified); PREP (Preparation); USES (Uses)
(silver halide photog. material containing anilinoimidazole to develop dye image with high spectral absorption)

RN 179421-93-3 CAPLUS
CN Pentanamide, N-[4-[2-(acetylamino)phenyl]-5-[[4-(diethylamino)-2-methylphenyl]amino]-1H-imidazol-2-yl]- (CA INDEX NAME)



L15 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:183280 CAPLUS
DOCUMENT NUMBER: 122:55805
ORIGINAL REFERENCE NO.: 122:10814h,10815a
TITLE: A Simple and Practical Synthesis of 2-Aminoimidazoles
AUTHOR(S): Little, Thomas L.; Webber, Stephen E.
CORPORATE SOURCE: Agouron Pharmaceuticals Inc., San Diego, CA, 92121, USA
SOURCE: Journal of Organic Chemistry (1994), 59(24), 7299-305
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 122:55805
AB A new and simple two-step procedure to synthesize 2-aminoimidazoles (2-AI's) from readily available materials has been developed. The cyclization reaction of α-halo ketones RCOCHR1X [R = Me, Et, CMe3, Ph, 4-BrC6H4, etc., R1 = H, Me, Ph, RR1 = (CH2)3, (CH2)4, X = Cl, Br] and N-acetylguanidine in acetonitrile (MeCN) at reflux, or in DMF at ambient temperature, gives 4(5)-substituted and 4,5-disubstituted N-(1H-imidazol-2-yl)acetamides I, which are then hydrolyzed to their resp. 2-AI's. In general, the purified products were isolated in good yields. We have prepared several examples and have demonstrated the usefulness of this method by its application in the total synthesis of 2-aminohistamine, an interesting histamine analog, and oroidin (II), a marine natural product isolated from various sponges.
IT 160041-64-5P 160041-65-6P 160041-66-7P
160041-67-8P 160041-68-9P 160041-69-0P
160072-51-5P 160072-52-6P 160072-53-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminoimidazoles, aminohistamine, and oroidin by cyclization of carbonyl with acetylguanidine)
RN 160041-64-5 CAPLUS
CN Acetamide, N-(5-phenyl-1H-imidazol-2-yl)- (CA INDEX NAME)



RN 160041-65-6 CAPLUS

CN Acetamide, N-[5-(4-methylphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 160041-66-7 CAPLUS
CN Acetamide, N-[5-(4-bromophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 160041-67-8 CAPLUS
CN Acetamide, N-[5-(4-methoxyphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 160041-68-9 CAPLUS
CN Acetamide, N-[5-(3-nitrophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 160041-69-0 CAPLUS
CN Acetamide, N-[5-(3-phenoxyphenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 160072-51-5 CAPLUS
CN Acetamide, N-(4-methyl-5-phenyl-1H-imidazol-2-yl)- (CA INDEX NAME)



RN 160072-52-6 CAPLUS
CN Acetamide, N-(4,5-diphenyl-1H-imidazol-2-yl)- (CA INDEX NAME)



RN 160072-53-7 CAPLUS
CN Acetamide, N-[5-(2-naphthalenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



L15 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:540469 CAPLUS
DOCUMENT NUMBER: 117:140469
ORIGINAL REFERENCE NO.: 117:24183a,24186a
TITLE: Cyan coupler-containing photographic material
INVENTOR(S): Nakayama, Noritaka; Uchida, Taku; Masukawa, Toyoaki
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03284746	A	19911216	JP 1990-86760	19900330 <--

PRIORITY APPLN. INFO.: JP 1990-86760 19900330
AB In the title photog. material containing ≥1 Ag halide emulsion layers, ≥1 of the Ag halide emulsion layer contains a cyan coupler (I) [R = H, substituent; L = divalent linking group; R1 = proton donor which may H-bond with N of the parent ring; R2 = substituent; m = 1-4; X = H, group releasable on coupling with an oxidized color developing agent]. The cyan dye produced by this coupler has good spectral absorption characteristics with sharp cutoff at the shortwave side, unsym. absorption is not observed in the blue and green regions, and color reproducibility is superior.
IT 143316-84-1P
RL: PREP (Preparation)
(preparation of, as photog. cyan coupler)
RN 143316-84-1 CAPLUS
CN Butanamide, N-[2-[2-(acetylamino)-5-chloro-1H-imidazol-4-yl]-4-ethoxyphenyl]-2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-3-methyl- (CA INDEX NAME)



L15 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:13220 CAPLUS
DOCUMENT NUMBER: 116:13220
ORIGINAL REFERENCE NO.: 116:2279a,2282a
TITLE: Heat developable color photographic material
INVENTOR(S): Miura, Akio; Masukawa, Toyoaki; Komamura, Tawara
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03089343	A	19910415	JP 1989-227154	19890901 <--
PRIORITY APPLN. INFO.:			JP 1989-227154	19890901

AB The title material on a support comprises photosensitive silver halide, a reducing agent, a binder, and cyan dye-forming coupler I (A, B = organic group connected to the imidazole ring by the C, N, O, or S atom; X = H, group which is released upon coupling reaction with the oxidized form of the reducing agent). I (A = Q1, B = Q2; X = Q3) is an example of the general structure I defined above. The use of I provides stable cyan dyes and gives excellent cyan dye images.

IT 137590-60-4
RL: USES (Uses)
(cyan dye-forming coupler, in photog. material)

RN 137590-60-4 CAPLUS

CN Propanoic acid, 3-[[4-[2-[[2-[2,4-bis(1,1-dimethylpropyl)phenyl]acetyl]amino]phenyl]-2-[(1-oxopentyl)amino]-1H-imidazol-5-yl]thio]- (CA INDEX NAME)





L15 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:408016 CAPLUS
DOCUMENT NUMBER: 113:8016
ORIGINAL REFERENCE NO.: 113:1505a,1508a
TITLE: Imidazole dyes for thermal-transfer printing inks
INVENTOR(S): Uchida, Taku; Masukawa, Toyoaki; Nakayama, Noritaka
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02028264	A	19900130	JP 1988-177357	19880715 <--
PRIORITY APPLN. INFO.:			JP 1988-177357	19880715

OTHER SOURCE(S): MARPAT 113:8016

AB The title dyes, with lower undesired absorption than indoaniline dyes and better heat and light resistance than cyanine dyes, have the general formula I [R1, R2 = H, (un)substituted alkyl; R1,R2 = 5- or 6-membered ring member; R3-6 = H, halogen, (un)substituted alkyl, alkoxy; R7 = H, (un)substituted alkyl, aryl, R11CO, R11O2C, R12NHCO, R13R14NCO, R11SO2, R11OSO2, R12NHSO2, R13R14NSO2; R11 = H, (un)substituted alkyl; R12 = (un)substituted aryl, heterocyclic, R13, R14 = (un)substituted alkyl; X = CO, SO2, NHCO; R8 = (un)substituted alkyl, Q; R9, R10 = monovalent group; n = 0-4; n = 0-5]. Benzaldehyde guanyl hydrazone and 2-[2-(2,4-di-tert-amylphenoxy)isopentanamido]phenacylbromide in CHCl3 were refluxed for 10 min and stirred at room temperature for 1 h to give 2-benzylidenehydrazino-4-[2-[2-(2,4-di-tert-amylphenoxy)isopentanaido]phenyl]imidazole, which was stirred with Zn/HCl in acetone to give 2-amino-4-[2-[2-(2,4-di-tert-amylphenoxy)isopentamido]phenyl]imidazole. This product was treated with BzCl in the presence of NaOAc in EtOAc to give 2-amino-3-benzoyl-4-[2-[2-(2,4-di-tert-amylphenoxy)isopentanamido]phenyl]imidazole, which was then heated with p-MeC6H4SO3H in PhNO2 at 150° for 1 h to give 2-benzoylamino-4-[2-[2-(2,4-di-tert-

amylphenoxy)isopentanamido]phenyl]imidazole, which was then dissolved in EtOAc, stirred with aqueous K2CO3, treated with aqueous 4-amino-3-methyl-N-methyl-N-(β-methanesulfonamidomethyl)aniline sulfate, then with 10% aqueous K2S2O8 to give I [R1 = Et; R2 = CH2Ch2NHSO2Me; R2 = Me; R4 = R5 = R6 = R9 = H; R7 = 2-(2,4-di-tert-amylphenoxyispropanoyl)].

IT 127698-35-5P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(manufacture and reaction of, with aniline derivs.)

RN 127698-35-5 CAPLUS

CN Butanamide, N-[2-[2-(acetylamino)-1H-imidazol-5-yl]phenyl]-2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-3-methyl- (CA INDEX NAME)



L15 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:32967 CAPLUS

DOCUMENT NUMBER: 106:32967

ORIGINAL REFERENCE NO.: 106:5527a,5530a

TITLE: Heterocyclic rearrangements. Rearrangement of N-(1,2,4-oxadiazol-3-yl)-β-enamino ketones to pyrimidine N-oxides

AUTHOR(S): Vivona, Nicolo; Buscemi, Silvestre; Frenna, Vincenzo; Ruccia, Michele

CORPORATE SOURCE: Inst. Org. Chem., Univ. Palermo, Palermo, 90123, Italy

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1986), (1), 17-19
CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:32967

AB The behavior of oxadiazolylenamino ketones I (R, R1 = Me, Ph; R2 = Me, Ph, OEt) towards rearrangement has been investigated. In the presence of anionic reagents in ethanol solution, they rearrange to pyrimidine N-oxides II (R3 = Me, Ph). The synthesis and hydrolytic ring opening of an oxadiazolopyrimidinium system III is also reported.

IT 55729-99-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 55729-99-2 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-(acetylamino)-5-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L15 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:185082 CAPLUS
DOCUMENT NUMBER: 102:185082
ORIGINAL REFERENCE NO.: 102:29037a,29040a
TITLE: Amidine derivatives of 2-substituted 4-phenylimidazole
INVENTOR(S): Bietti, Giuseppe; Cereda, Enzo; Donetti, Arturo; Giachetti, Antonio; Pagani, Ferdinando
PATENT ASSIGNEE(S): Istituto De Angeli S.p.A., Italy
SOURCE: Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 131973	A1	19850123	EP 1984-200659	19840508 <--
EP 131973	B1	19890802		
R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
AT 45149	T	19890815	AT 1984-200659	19840508 <--
US 4649150	A	19870310	US 1984-610958	19840516 <--
FI 8402432	A	19850119	FI 1984-2432	19840615 <--
JP 60038367	A	19850227	JP 1984-142099	19840709 <--
DD 232696	A5	19860205	DD 1984-265319	19840716 <--
PL 143303	B1	19880229	PL 1984-248779	19840716 <--
IL 72417	A	19880331	IL 1984-72417	19840716 <--
PL 143732	B1	19880331	PL 1984-254625	19840716 <--
DK 8403500	A	19850119	DK 1984-3500	19840717 <--
NO 8402921	A	19850121	NO 1984-2921	19840717 <--
NO 162857	B	19891120		
NO 162857	C	19900228		
HU 34959	A2	19850528	HU 1984-2781	19840717 <--
HU 193292	B	19870928		
GB 2149395	A	19850612	GB 1984-18149	19840717 <--
GB 2149395	B	19861126		
ZA 8405490	A	19860326	ZA 1984-5490	19840717 <--
SU 1322979	A3	19870707	SU 1984-3770847	19840717 <--
CA 1257274	A1	19890711	CA 1984-459030	19840717 <--
AU 8430800	A	19850124	AU 1984-30800	19840718 <--
AU 565292	B2	19870910		
CS 244141	B2	19860717	CS 1984-5542	19840718 <--
SU 1313345	A3	19870523	SU 1985-3844125	19850129 <--
CS 244150	B2	19860717	CS 1985-2801	19850416 <--

PRIORITY APPLN. INFO.:

IT 1983-22110	A	19830718
EP 1984-200659	A	19840508
CS 1984-5542	A3	19840718

OTHER SOURCE(S): MARPAT 102:185082

AB Forty-four (amidinophenyl)imidazoles I [R = alkyl, OH, alkoxy, SH, alkylthio, halo, alkylsulfinyl, alkylsulfonyl, SO2NH2, (di)(alkyl)amino, acylamino, Ph; R1, R2 = H, alkyl; R3 = alkyl optionally containing 1 hetero atom such as O, S, or N, alkenyl, alkynyl, cyano, cycloalkyl, cycloaliph.

alkyl, (un)substituted aryl, aralkyl, heterocyclylalkyl, heterocyclyl; R4 = H, alkyl, alkoxy, halo, cyano, CONH2] were prepared Thus, 4-O2NC6H4COCH2Br in water was treated with AcNH2 at 140° for 8 h to give phenylimidazole II (R5 = NO2), which was catalytically reduced to II (R5 = NH2). The latter compound was condensed with EtOCH:NCN to give II (R5 = N:CHNHCN), which was treated with EtNH2 to give II (R5 = N:CHNHEt)(III). III inhibited histamine-induced tachycardia in isolated guinea pig atria with an EC50 of 1.5 + 10-7M.

IT 96139-96-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with isopropylamine)

RN 96139-96-7 CAPLUS

CN Acetamide, N-[5-[4-[[(cyanoamino)methylene]amino]phenyl]-1H-imidazol-2-yl]- (CA INDEX NAME)



IT 96139-70-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 96139-70-7 CAPLUS

CN Acetamide, N-[5-(4-nitrophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



IT 96154-06-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 96154-06-2 CAPLUS

CN Acetamide, N-[4-[4-[[[(1-methylethyl)amino]methylene]amino]phenyl]-1H-imidazol-2-yl]-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 96154-05-1
CMF C15 H19 N5 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT 96139-64-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, hydride reduction, and reaction of, with cyanoformimidate)
RN 96139-64-9 CAPLUS
CN Acetamide, N-[5-(4-aminophenyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



L15 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:112006 CAPLUS
DOCUMENT NUMBER: 82:112006
ORIGINAL REFERENCE NO.: 82:17899a,17902a
TITLE: Mononuclear heterocyclic rearrangements. VI. Conversion of 1,2,4-oxadiazoles into imidazoles
AUTHOR(S): Ruccia, M.; Vivona, N.; Cusmano, G.
CORPORATE SOURCE: Fac. Sci., Univ. Palermo, Palermo, Italy
SOURCE: Tetrahedron (1974), 30(21), 3859-64
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 82:112006
AB Condensation of aminooxadiazoles with β-oxo ketones or esters gave β-enamino ketones, which with NaOEt in DMF rearranged to imidazole derivs. E.g., I with (MeCO)2CH2 gave II, which with NaOEt in DMF gave III. Condensation of I with PhCOCH2CO2Et gave IV and V. V was in solution equilibrium with its tautomer VI.
IT 55729-99-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55729-99-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-(acetylamino)-5-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L15 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1962:46003 CAPLUS
DOCUMENT NUMBER: 56:46003
ORIGINAL REFERENCE NO.: 56:8702f-i,8703a-e
TITLE: 2-Phenylhydrazinoimidazoles and their benzidine-like rearrangement
AUTHOR(S): Pyl, Theodor; Lahmer, Helmut; Beyer, Hans
CORPORATE SOURCE: Univ. Greifswald, Germany
SOURCE: Chemische Berichte (1961), 94, 3217-23
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 56:46003

AB PhNHC(:NH)NH2 (I) reacts with BzCH2Br (II) and its aryl analogs to yield the corresponding 2-phenylhydrazinoimidazoles (III) which undergo with concentrated HCl a benzidine-like rearrangement. The structure was proved by the rearrangement of 2-phenylhydrazino-4(5)-phenylimidazole (IV) to 2-amino-4-phenyl-5-(p-aminophenyl)imidazole (V) and subsequent deamination to the known 2-amino-4,5-diphenylimidazole (VI). The lack of reducing properties in the III indicates the presence of the tautomeric 2-imidazolone phenylhydrazone form. I.HCl (3.73 g.) in 25 cc. MeOH treated with cooling with 0.46 g. Na in 20 cc. MeOH, filtered, and treated with 2 g. II in Me2CO gave 1.5 g. IV, needles, m. 225-6° (decomposition) (BuOH), turned yellow to pink in air; IV.HCl, rodlets, m. 201° (decomposition) (BuOH). IV refluxed 1 hr. with excess Ac2O in C5H5N gave the di-Ac derivative (VII) of IV, leaflets, m. 232° (decomposition) (1:1 BuOH-EtOH); di-Bz derivative, yellowish powder, decomposing above 230° with darkening. I.HCl (3.73 g.) and 2.78 g. p-BrC6H4COCH2Br gave 1.5 g. 4(5)-p-BrC6H4 analog (VIII) of IV, needles, m. 227° (decomposition) (BuOH); VIII.HCl, rodlets, m. 215° (decomposition); di-Ac derivative of VIII, yellowish microcryst. powder, m. 155-6° (aqueous EtOH). I.HCl (3.73 g.) with 1.86 g. p-MeC6H4COCH2Cl gave 1.5 g. 4(5)-p-MeC6H4 analog (IX) of IV, needles, m. 223-4°, (BuOH); IX.HCl, rodlets, m. 198° (decomposition); di-Ac derivative of IX, rodlets, m. 272-3° (aqueous EtOH). I.HCl (3.73 g.) with 2.3 g. p-MeOC6H4COCH2Br yielded 1.6 g. 4(5)-p-MeOC6H4 analog of IV, needles, m. 215-16° (decomposition); IV.HCl, rodlets, m. 213- 14° (decomposition) (BuOH); di-Ac derivative, yellowish crystal powder, m. 172-3°. IV (0.5 g.) in 3 cc. o-HOC6H4CHO refluxed briefly, cooled, diluted with 2 vols. EtOH, and filtered gave nearly 100% 4-phenyl-5-salicylidene-2-imidazolone phenylhydrazone (X), yellow needles, m. 230° (decomposition) (EtOH). Similarly were prepared the following 4-aryl analogs of X (aryl group and m.p. given): p-BrC6H4 213° (decomposition) (EtOH), p-MeC6H4 234° (decomposition) (EtOH); p-MeOC6H4 211° (decomposition) (EtOH); all yellow needles. VII (4 g.) and 40 cc. concentrated HCl refluxed 5 hrs., concentrated to beginning crystallization, cooled, and filtered gave 2 g. V.2HCl, needles, m. 310° (decomposition). IV (30 g.) and 250 cc. concentrated HCl refluxed, and the precipitate dissolved in a little H2O and repptd. with concentrated HCl gave 8 g. V.2HCl, needles, m. 310° (decomposition). V.2HCl in H2O treated with NH4OH gave V, yellowish rodlets, m. 265° (decomposition). V and excess Ac2O refluxed 1 hr. gave the di-Ac derivative, needles, m. 261° (EtOH). VIII (25 g.) in 250 cc. concentrated HCl refluxed 5 hrs., cooled, decanted from some resin, kept some time, filtered, and concentrated, and the precipitate dissolved in a little cold H2O and repptd. with concentrated HCl gave 3 g. 4-(p-BrC6H4) analog (X.2HCl) of V.2HCl, needles, m. 220° (decomposition). X.2HCl in H2O treated with dilute NH4OH gave X, powder, decomposing above 310° (aqueous EtOH). IX (26 g.) yielded similarly 8 g. 4-(p-MeC6H4) analog of

V.2HCl, needles, m. 305°; free base, colorless prisms, decompose 303°; di-Ac derivative, yellowish crystal powder, m. 296° (EtOH). V (2 g.) in 5 cc. concentrated HCl and 50 cc. H2O treated at 0° with 0.6 g. NaNO2 in 5 cc. H2O and added to 1 g. 2-C10H7OH in 100 cc. 20% aqueous NaOH, and the violet flocculent precipitate washed with H2O, dissolved in 100 cc. hot EtOH, filtered, and diluted with H2O and a few drops HCl gave 0.8 g. 5-[p-(2-C10H7N:N)C6H4] analog of V, brown-violet powder, decomposing at higher temperature without melting, red-violet in organic solvents. Diazotized V added to aqueous H3PO2, and the crystalline precipitate crystallized from dilute HCl, dissolved in MeOH, treated with dilute aqueous NaOH, and diluted with H2O yielded VI, prisms, m. 243° (decomposition).

IT 98783-56-3P, Acetanilide, 4'-[2-acetamido-5(or 4)-phenylimidazol-4-(or 5)-yl]- 99080-81-6P, Acetanilide, 4'-[2-acetamido-5(or 4)-p-tolylimidazol-4-(or 5)-yl]-
RL: PREP (Preparation)
(preparation of)

RN 98783-56-3 CAPLUS
CN Acetanilide, 4'-[2-acetamido-5(or 4)-phenylimidazol-4(or 5)-yl]- (7CI) (CA INDEX NAME)



RN 99080-81-6 CAPLUS
CN Acetanilide, 4'-[2-acetamido-5(or 4)-p-tolylimidazol-4(or 5)-yl]- (7CI) (CA INDEX NAME)



L15 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1919:6989 CAPLUS
DOCUMENT NUMBER:	13:6989
ORIGINAL REFERENCE NO.:	13:1301f-i,1302a-i,1303a-i,1304a-b
TITLE:	Nitro-, arylazo-, and aminoglyoxalines
AUTHOR(S):	Fargher, Robert George; Pyman, Frank Lee
CORPORATE SOURCE:	Welcome Chem. Res. Lab., London
SOURCE:	Journal of the Chemical Society, Transactions (1919), 115, 217-60 CODEN: JCHTA3; ISSN: 0368-1645
DOCUMENT TYPE:	Journal

LANGUAGE: Unavailable

AB cf. C. A. 10, 1631. All m. ps. are corr. The object of this investigation was to prepare purine derivs. by building up a pyrimidine ring upon a glyoxaline nucleus, a method complementary to the usual one. It was proposed to prepare 4-aminoglyoxaline-5-carboxylic acid, CH:N.C(NH2):C(CO2H).NH, condense it with HCNO and obtain xanthine. The synthesis was not accomplished because of inability to obtain the starting material. I. The preparation of glyoxalines and their carboxylic acids: Glyoxaline-4,5-dicarboxylic acid (a), prepared in 60% yield by mixing cold aqueous solns. of nitrotartaric acid and CH2O, m. 288° (decomposition). Mono-sodium salt, forms feathery needles containing 1 H2O. Glyoxaline (b) is prepared by distilling (a) in small quantities at a time; picrate, yellow needles containing 1 H2O, m. 212°; hydrogen tartrate, anhydrous prisms, m. 202°; hydrogen oxalate, anhydrous prismatic needles, m. 232°. On heating (a) to above 180° with H2o or HCL the main product is (b) with a little glyoxaline-4-carboxylic acid. When (a) is heated to 180-200° with concentrated NH4OH the main product is (b). On boiling (a) with PhNH2 the main product is glyoxaline-4-carboxanilide, anhydrous needles, m. 227-8°, hydrolyzed by 10% HCl at 130°, producing glyoxaline-4-carboxylic acid.
2-Methylglyoxaline-4,5-dicarboxylic acid (c) is prepared from AcH and nitrotartaric acid in 67% yield. On boiling (c) with PhNH2 there is obtained 11 g. 2-methyl-glyoxaline-4-carboxanilide (d), m. 208°, and 3.8 g. 2-methylglyoxaline; picrate, anhydrous needles from H2O, m. 213°; hydrogen oxalate, rhombic prisms from H2O containing 2 H2O; after drying at 100° it m. 160°. Hydrolysis of (d) gives 2-methylglyoxaline-4-carboxylic acid as a monohydrate, prismatic needles, m. 262° (decomposition); nitrate, rhombic prisms from H2O, m. 190°; picrate, minute cubes containing 2H2O, m. 200°.
2-Ethylglyoxaline-4,5-dicarboxylic acid, prepared from EtCHO and nitrotartaric acid in 64% yield, m. 259° (decomposition).
2-Phenylglyoxaline-4,5-dicarboxylic acid, from BzH and nitrotartaric acid in 48% yield, m. 271° (decomposition). When distilled in small quantities it gives an 80% yield of 2-phenylglyoxaline, needles from H2O, m. 148-9°; nitrate, leaflets from alc. containing 0.75 H2O, m. (dry) 135°; hydrogen oxalate, needles, m. 219° (decomposition); picrate, fine needles, m. 238°. Upon mixing 8.6 g. Ac2 in 50 cc. H2O, 50 cc. of 40% aqueous CH2O, and 80 cc. concentrated NH4OH at 0° there is obtained after standing in a cool place overnight, evaporating to a small bulk, saturating with K2CO3, extracting with Et2O, and evaporating the extract, 5.9 g. of an oil which is boiled with dilute HCl to destroy C6H12N4 and separated by fractionating the picrates from H2O into 5.7 g. 4,5-dimethylglyoxaline picrate (e), and 3.5 g. 2,4,5-trimethylglyoxaline picrate, m. 163°.
4,5-Dimethylglyoxaline hydrochloride forms rhombic prisms from H2O, m. 305° (decomposition). (e) is also prepared from MeCOC(:NOH)Me (9 g.) by reducing with SnCl2 at is 15° and evaporating the final liquor under reduced pressure; the resulting 10 g. MeCOCH(NH2)Me heated on the H2O bath 4 hrs. with 10 g. KCNS and 40 cc. H2O gives 5.2 g. 2-thiol-4,5-dimethylglyoxaline and the latter gives an 85% yield of (e) when oxidized with the calculated quantity of FeCl3. II. Nitroglyoxalines: 4-Nitroglyoxaline (f) is obtained in 63% yield when 8 g. of (b) in 16 cc. cold HNO3 (1.4), is cautiously treated with 16 cc. H2SO4, and after the vigorous reaction is over boiled 2 hrs. and poured into ice-H2O. 4-Nitro-2-methylglyoxaline, (g), prepared similarly, anhydrous needles from H2O, sinter 251°, m. 254°. On nitrating 4-methylglyoxaline by the method of Windaus (C. A. 3, 1268) the main product is 4-methylglyoxaline nitrate instead of 5-nitro-4-methylglyoxaline (h) as stated by him. (h), obtained in 90% yield by the method described for preparing (g), m. 248°. On attempting to nitrate 4,5-dimethylglyoxaline (5 g.) with HNO3 and H2SO4 1.7 g. was recovered

unchanged and the only product was 0.3 g. of the nitrate of 4-methylglyoxaline-5-carboxylic acid. When (f), (g), or (h) are reduced with Sn and HCl two of the three atoms of N present are eliminated as NH3. Three mols. (f) on reduction with alkaline Na2S2O4 loses 2 atoms N as NH3. The remaining liquor gradually acquired a blue color as noted by Behrend and Schmitz (Ann. 277, 338) and on acidification precipitated less than 0.1 g. of a blue compound m. above 300°. (h) on reduction behaved analogously but gave a rose color and no precipitate (g) gave 1 mol. of NH3 from 3 mols. of the nitro-compound III. Arylazoglyoxalines: In the opinion of the authors it appears that glyoxalines, in order to be capable of coupling, must contain a free « NH group and also a H atom or some other displaceable group, such as CO2H, in one of the 2-, 4-, or 5-positions. All previously prepared arylazoglyoxalines are C-azo compds. In general, the monoarylazoglyoxalines are soluble in alc., EtOAc and Me2CO, sparingly soluble in Et2O, CHCl3 and C6H6, insol, in cold H2O and dilute alkali, form soluble salts with dilute HCl; are decomposed by boiling 1 hr. with 10% HCl, give bright colors with concentrated H2SO4. 17 g. (b) and 40 g. Na2CO3 in 125 cc. H2O treated at 5° with a diazotized solution of 23.25 g. PhNH2 give an orange powder which, on extracting with cold 2.5% HCl, left 4.4 g. residue of 2,4,5-trisbenzeneazoglyoxaline, decomps. about 200°, effervesces 208°. The HCl extract made alkaline gave 34 g. 2-benzeneazoglyoxaflne (i), m. 190°. 20 g. of (i) reduced with SnCl2 gives 3.2 g. 2-aminoglyoxaline, chlorostannate, a trace of NH2C(:NH)NH2, and 18.55 g. 2-amino-4-p-aminophenylglyoxaline dihydrochloride (j), formed by rearrangement of the benzidine type, m. above 300°; free base, formed by boiling with Na2CO3, glistening leaflets containing 1 H2O, m. 148°; dipicrate, yellow needles, darken 245°, M. 250° (decomposition). 2-Acetylamino-4-p-acetylaminophenylglyoxaline, by boiling the base with Ac2O 1 hr., crystalline powder, m. above 300°. 10 g. in dilute H2SO4 with 4% KMnO4 gave 1 g. p-AcNHC6H4CO2H, m. 260°. Reduction of 17.2 g. (i) with Zn dust and AcOH gives a small amount of (j), 7 g. PhNH2, and 5.9 g. of pure glycocyamidine hydrochloride (k), sintered 205°, m. 211-3°; free base, prismatic needles. begins darkening 220° and does not m. 300°; chloroplatinate, C3H5ON3.H2PtCl6.2H2O, darkens 220°, entirely black at 260°, does not m. 300°; chloraurate, C3H5ON3.AuCl3, m. 157-8°; picrate, yellow leaflets, m. 215-16°. By treating 13.6 g. (b) in Na2CO3 at 5° with a diazotized solution of 34.4 g. p-BrC6H4NH2 there resulted 48.7 g. crude 2-p-bromobenzeneazoglyoxaline (l); crystallization from alc. gave 42.6 g. of the pure compound m. 253° (decomposition) and a small amount of 4-p-bromobenzeneazoglyoxaline, m. 191° (decomposition). (l) (78 g.) on reduction with SnCl2 gave 40.7 g. p-BrC6H4NH2, 2.7 g. of 2-amino-4-p-aminophenylglyoxaline, isolated as the picrate, 1.6 g. NH2C(:NH)NH2.(CO2H)2, m. 173-4°, 0.9 g. of a base forming needles, m. 178°, probably having the structure 5,2-Br(H2N)C6H3NHC:N.CH:CH.NH, and 20.7 g. 2-aminoglyoxaline hydrochloride (m), plates from alc., m. 152°; free base, obtained as a colorless sirup by adding 1 equivalent of Na2CO3, evaporating to dryness, extracting with alc., and evaporating the alc.; chlorostannate, prismatic needles, m. 286°; nitrate, transparent tablets, sinter 125°, m. 135-6°; hydrogen oxalate, tablets, m. 211°; picrate, silky needles, m. 236°. 2-Acetylaminoglyoxaline, prepared by boiling (m) with Ac2O and AcONa, prisms, sinter 270°, m. 287°. 2-Benzoylaminoglyoxaline, prepared by Schotten-Baumann reaction, leaflets, m. 227°. 4-Methylglyoxaline (32.8 g.) in NaHCO3 treated with PhN:NCl gave 17.3 g. 2,5-bisbenzeneazo-4-methylgtyoxaldne, garnet-red needles from alc., m. 206° (decomposition); 17 g. of 5-benseneazo-4-methylglyoxaline (n), copper-colored needles, m.

240° (decomposition); 7.4 g. of 2-benzeneazo-4-methylglyoxatine (o), orange prisms, m. 185°. Reduced with SnCl2 (o) gives 2-amino-5-p-amixophenyl-4-methylglyoxaline dihydrochloride (p), diamond-shaped plates, m. above 300°. (p) boiled with Na2CO3 gives the monohydrochloride, flat needles, sinter 80°, m. 260°; dipicrate, yellow needles, m. 255°.
2-Acetylamino-5-p-acetylaminophenyl-4-methylglyoxaline hydrochloride, prepared by the action of Ac2O and AcONa on (p), needles containing 4 H2O, after drying at 100° m. 303° (decomposition). On adding NH4OH to the solution of the hydrochloride the free base is precipitated, needles, m. 280°. 2-Amino-5-p-benzylideneaminophenyl-4-methylglyoxali neacetate, prepared by adding BzH to (p) in AcONa solution, m. 208°. (o) on reduction with Zn and AcOH gave 1.4 g. brown sirup from which was separated a small quantity of the dipicrate of (p) and about 0.7 g. alacreatinine hydrochloride, prisms, m. 202-3°; free base, m. 222-3°; picrale, yellow needles, sinter 200°, m. 212°. On reduction of 14 g. of (n) with SnCl2 there is obtained besides PhNH2 and a brown gum, 2.2 g. of the hydrochloride, C9H10ON2.HCl, rectangular tablets, m. 308°, from which a base, C3H10ON2, is obtained by adding NH4OH and crystallizing from H2O, prisms, m. 185°. Reduction of 10. g. (n) with Zn and AcOH produced 5.5 g. of a varnish-like substance and 1.6 g. of the base C10HON3, small, rhomboidal plates, m. 265°; hydrochloride, oblong plates, m. 206-8°, decomposed by heating 2.5 hrs. at 170° into NH4Cl and a hydrochloride, m. about 280°.
2-Methylglyoxaline in Na2CO3 treated with PhN:NCl gives a product which easily resinifies and from which a small amount of 4-benzeneazo-2-methylglyoxaline was obtained pure, m. 158°.
4-p-Bromobenzeneazo-2-methylglyoxaline, prepared in good yield from 2-methylglyoxaline in Na2CO3 and p-BrC6H4N:NCl, red prism sfrom absolute alc., m. 200° (decomposition); reduction with either SnCl2 or Zn and AcOH give no definite products. 2-Phenylglyoxaline (7.2 g.) heated with p-BrC6H4N:NCl gives 13 g. 2-phenyl-4-p-bromobenzeneazoglyoxaline (q), orange needles, m. 201°. Reduction of (g) with SnCl2 gives a crystalline hydrochloride, C15H13N4Br.2HCl, m. 255°; triacetyl derivative, formed by heating with Ac2O and AcONa, m. above 300°. This base is probably the result of a change of the semidine or benzidine type. 2-p-Sulfobenzeneazoglyoxaline-4,5-dicarboxylic acid, prepared by treating glyoxaline-4,5-dicarboxylic acid with SO3HC6H4N:NCl, red prisms containing 2 H2O which are lost at 130° in vacao; disodium salt (r), yellow, silky needles containing 3 H2O. Reduction of 6.2 g. (r) with Na2S2O4 gives 1.6 g. of 2-aminoglyoxaline-4,5-dicarboxylic acid, pale buff needles, effervesce 245° and then melt. On boiling 6 hrs. with PhNH2 the product was identified as (m).

IT 861294-61-3P, Imidazole, 2-acetamido-4-(p-acetamidophenyl)-
861325-21-5P, Imidazole, 2-acetamido-5-(p-acetamidophenyl)-4-methyl-, hydrochloride 861325-23-7P, Acetanilide, p-(2-acetamido-4-methyl-5-imidazolyl)-
RL: PREP (Preparation)
(preparation of)

RN 861294-61-3 CAPLUS

CN Acetamide, N-[4-[2-(acetylamino)-1H-imidazol-5-yl]phenyl]- (CA INDEX NAME)



RN 861325-21-5 CAPLUS
CN Acetamide, N-[4-[2-(acetylamino)-4-methyl-1H-imidazol-5-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 861325-23-7 CAPLUS
CN Acetamide, N-[4-[2-(acetylamino)-4-methyl-1H-imidazol-5-yl]phenyl]- (CA INDEX NAME)



=> ....Testing the current file.... screen

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Please change to a suitable file and repeat your upload

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	138.96	782.13
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-19.20	-32.00

FILE 'REGISTRY' ENTERED AT 11:54:29 ON 27 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 OCT 2008 HIGHEST RN 1065816-63-8

DICTIONARY FILE UPDATES: 24 OCT 2008 HIGHEST RN 1065816-63-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\STNEXP\Queries\10564010 str 5.str

L18   STRUCTURE UPLOADED

=> que L18

L19 QUE L18

=> d l19
L19 HAS NO ANSWERS
L18   STR



Structure attributes must be viewed using STN Express query preparation.
L19   QUE ABB=ON PLU=ON L18

=> s l19 sss full

```
FULL SEARCH INITIATED 11:55:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      599 TO ITERATE

100.0% PROCESSED      599 ITERATIONS                              14 ANSWERS
SEARCH TIME: 00.00.01

L20          14 SEA SSS FUL L18

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 178.82     960.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00     -32.00

FILE 'CAPLUS' ENTERED AT 11:55:38 ON 27 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 27 Oct 2008  VOL 149 ISS 18
FILE LAST UPDATED: 26 Oct 2008  (20081026/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> d hi
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y


'HI' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual
fields or predefined formats.  The predefined substance formats
are:  (RN = CAS Registry Number)

REG     - RN
SAM     - Index Name, MF, and structure - no RN
FIDE    - All substance data, except sequence data
IDE     - FIDE, but only 50 names
```

```
SQIDE  - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD    - Protein sequence data, includes RN
SQD3   - Same as SQD, but 3-letter amino acid codes are used
SQN    - Protein sequence name information, includes RN

EPROP  - Table of experimental properties
PPROP  - Table of predicted properties
PROP   - EPROP, ETAG, PPROP and SPEC

Any CA File format may be combined with any substance format to
obtain CA references citing the substance.  The substance formats
must be cited first.  The CA File predefined formats are:

ABS  -- Abstract
APPS -- Application and Priority Information
BIB  -- CA Accession Number, plus Bibliographic Data
CAN  -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND  -- Index Data
IPC  -- International Patent Classification
PATS -- PI, SO
STD  -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when
it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented,
with text labels.

For additional information, please consult the following help
messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):d his
'D' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual
fields or predefined formats.  The predefined substance formats
are:  (RN = CAS Registry Number)

REG    - RN
SAM    - Index Name, MF, and structure - no RN
FIDE   - All substance data, except sequence data
IDE    - FIDE, but only 50 names
SQIDE  - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD    - Protein sequence data, includes RN
```

```
SQD3   - Same as SQD, but 3-letter amino acid codes are used
SQN    - Protein sequence name information, includes RN

EPROP  - Table of experimental properties
PPROP  - Table of predicted properties
PROP   - EPROP, ETAG, PPROP and SPEC

Any CA File format may be combined with any substance format to
obtain CA references citing the substance.  The substance formats
must be cited first.  The CA File predefined formats are:

ABS  -- Abstract
APPS -- Application and Priority Information
BIB  -- CA Accession Number, plus Bibliographic Data
CAN  -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND  -- Index Data
IPC  -- International Patent Classification
PATS -- PI, SO
STD  -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when
it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented,
with text labels.

For additional information, please consult the following help
messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):end

=> d his

     (FILE 'HOME' ENTERED AT 11:30:00 ON 27 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 11:30:38 ON 27 OCT 2008
L1               STRUCTURE UPLOADED
L2               QUE L1
L3           22 S L2 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:31:05 ON 27 OCT 2008
L4           22 S L3
L5           16 S L4 AND PY<=2004

     FILE 'REGISTRY' ENTERED AT 11:40:27 ON 27 OCT 2008
L6               STRUCTURE UPLOADED
L7               QUE L6
L8            1 S L7 SSS FULL
```

```
     FILE 'CAPLUS' ENTERED AT 11:40:57 ON 27 OCT 2008
L9             0 S L8
L10            0 S L8

     FILE 'REGISTRY' ENTERED AT 11:42:15 ON 27 OCT 2008
L11              STRUCTURE UPLOADED
L12              QUE L11
L13          126 S L12 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:42:56 ON 27 OCT 2008
L14           44 S L13
L15           24 S L14 AND PY<=2004
L16            0 S L15 AND 5-HYDROXYTRYPTAMINE
L17            0 S L15 AND 5HT

     FILE 'CAPLUS' ENTERED AT 11:44:31 ON 27 OCT 2008

     FILE 'REGISTRY' ENTERED AT 11:54:29 ON 27 OCT 2008
L18              STRUCTURE UPLOADED
L19              QUE L18
L20           14 S L19 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:55:38 ON 27 OCT 2008

     FILE 'REGISTRY' ENTERED AT 11:55:51 ON 27 OCT 2008

     FILE 'CAPLUS' ENTERED AT 11:55:58 ON 27 OCT 2008

=> file caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.48     962.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00     -32.00

FILE 'CAPLUS' ENTERED AT 11:56:07 ON 27 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 27 Oct 2008  VOL 149 ISS 18
FILE LAST UPDATED: 26 Oct 2008  (20081026/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
```

They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l20
L21          12 L20

=> s l21 and py<=2004
      25113423 PY<=2004
L22           3 L21 AND PY<=2004

=> d l22 1-3 ibib ab

L22  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:80450  CAPLUS
DOCUMENT NUMBER:          140:145835
TITLE:                    Preparation of dibenzofused
                          bicyclo[2.2.2]octane-derived amides as modulators of
                          the glucocorticoid receptor
INVENTOR(S):              Vaccaro, Wayne; Yang, Bingwei Vera; Kim, Soong-hoon;
                          Huynh, Tram; Tortolani, David R.; Leavitt, Kenneth J.;
                          Li, Wenying; Doweyko, Arthur M.; Chen, Xiao-tao;
                          Doweyko, Lidia
PATENT ASSIGNEE(S):       Bristol-Myers Squibb Company, USA; et al.
SOURCE:                   PCT Int. Appl., 265 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ----------------    ----   --------    --------------------    --------
     WO 2004009017        A2    20040129    WO 2003-US22300         20030717 <--
     WO 2004009017        A3    20040708
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003251970        A1    20040209    AU 2003-251970          20030717 <--
     US 20040132758       A1    20040708    US 2003-621909          20030717 <--
     US 6995181           B2    20060207
     EP 1534273           A2    20050601    EP 2003-765638          20030717
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006508042         T    20060309    JP 2004-523482          20030717
     NO 2005000074         A    20050309    NO 2005-74              20050106
     US 20050171136        A1   20050804    US 2005-85347           20050321
PRIORITY APPLN. INFO.:                     US 2002-396877P     P    20020718
                                           US 2003-621909      A1   20030717
                                           WO 2003-US22300     W    20030717

OTHER SOURCE(S):          MARPAT 140:145835
AB   Title compds. I [R-R4 = H, alk(en/yn)yl, alkoxy, aryl, etc.; Z =
     carboxamido, alkylamino, etc.] are prepared  For instance,
     2-amino-4,5-dimethylthiazole is coupled to the acid derived from the
```

cycloaddn. of methacrylic acid and anthracene (CH3CN, EDCI, Et3N, HOAt, 18 h) to give II. I are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders.

L22 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:80449 CAPLUS
DOCUMENT NUMBER: 140:157927
TITLE: Homology modeling of nuclear hormone receptor Site II and design of Site II ligands
INVENTOR(S): Doweyko, Arthur; Nadler, Steven G.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 276 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009016	A2	20040129	WO 2003-US22299	20030717 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1575502	A2	20050921	EP 2003-765637	20030717
EP 1575502	A3	20051123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060223110	A1	20061005	US 2003-621807	20030717
PRIORITY APPLN. INFO.:			US 2002-396907P P	20020718
			WO 2003-US22299 W	20030717

AB A binding site in nuclear hormone receptors is described and its structural coordinates are provided. The invention provides machine-readable data storage media comprising structure coordinates of Site II and computer systems comprising the machine-readable data storage media. The invention provides methods used in the design and identification of ligands of Site II and of modulators of nuclear hormone receptors. The invention provides ligands of Site II, modulators of NHRs, pharmaceutical compns. comprising modulators of NHRs, methods of modulating NHRs, and methods of treating diseases by administering modulators of an NHR. Also provided are methods of designing mutants, mutant NHRs, Site II binding assays, and models of Site II.

L22 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:84008 CAPLUS
DOCUMENT NUMBER: 94:84008
ORIGINAL REFERENCE NO.: 94:13701a,13704a
TITLE: Synthesis and halogenation of some new 2-amino-4-substituted imidazoles and their possible use as pesticides
AUTHOR(S): Nath, J. P.; Mahapatra, G. N.
CORPORATE SOURCE: Dep. Chem., Ravenshaw Coll., Cuttack, 753 003, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1980), 19B(6), 526-8
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 94:84008

AB Eleven imidazoles I (R = Ph, substituted Ph, α-, β-naphthyl, 2-thienyl; R1 = H) were prepared by cyclizing RAc with guanidine using Br as condensing agent. Halogenating I (R1 = H) gave I (R1 = Br, Cl). Both halogenated and nonhalogenated imidazoles exhibit antifungal activity against Piricularia oryzae and antibacterial activity against the common pathogenic bacteria, Staphylococcus aureus and Escherichia coli. Structure-activity relationship was also discussed.

=> d l22 1-3 ibib ab hitstr

L22 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:80450 CAPLUS
DOCUMENT NUMBER: 140:145835
TITLE: Preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of the glucocorticoid receptor
INVENTOR(S): Vaccaro, Wayne; Yang, Bingwei Vera; Kim, Soong-hoon; Huynh, Tram; Tortolani, David R.; Leavitt, Kenneth J.; Li, Wenying; Doweyko, Arthur M.; Chen, Xiao-tao; Doweyko, Lidia
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; et al.
SOURCE: PCT Int. Appl., 265 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009017	A2	20040129	WO 2003-US22300	20030717 <--
WO 2004009017	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003251970	A1	20040209	AU 2003-251970	20030717 <--
US 20040132758	A1	20040708	US 2003-621909	20030717 <--
US 6995181	B2	20060207		
EP 1534273	A2	20050601	EP 2003-765638	20030717
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508042	T	20060309	JP 2004-523482	20030717
NO 2005000074	A	20050309	NO 2005-74	20050106
US 20050171136	A1	20050804	US 2005-85347	20050321
PRIORITY APPLN. INFO.:			US 2002-396877P	P 20020718
			US 2003-621909	A1 20030717

OTHER SOURCE(S): MARPAT 140:145835

AB Title compds. I [R-R4 = H, alk(en/yn)yl, alkoxy, aryl, etc.; Z = carboxamido, alkylamino, etc.] are prepared For instance, 2-amino-4,5-dimethylthiazole is coupled to the acid derived from the cycloaddn. of methacrylic acid and anthracene (CH3CN, EDCI, Et3N, HOAt, 18 h) to give II. I are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders.

IT 650626-12-3 650626-16-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of glucocorticoid receptor)

RN 650626-12-3 CAPLUS
CN 1H-Imidazol-2-amine, 5-(4-fluoro-1-naphthalenyl)- (CA INDEX NAME)



RN 650626-16-7 CAPLUS
CN 1H-Imidazol-2-amine, 5-(6-methoxy-1-naphthalenyl)- (CA INDEX NAME)



L22 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:80449 CAPLUS
DOCUMENT NUMBER: 140:157927
TITLE: Homology modeling of nuclear hormone receptor Site II and design of Site II ligands
INVENTOR(S): Doweyko, Arthur; Nadler, Steven G.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 276 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009016	A2	20040129	WO 2003-US22299	20030717 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1575502	A2	20050921	EP 2003-765637	20030717
EP 1575502	A3	20051123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060223110	A1	20061005	US 2003-621807	20030717
PRIORITY APPLN. INFO.:			US 2002-396907P	P 20020718
			WO 2003-US22299	W 20030717

AB A binding site in nuclear hormone receptors is described and its structural coordinates are provided. The invention provides machine-readable data storage media comprising structure coordinates of Site II and computer systems comprising the machine-readable data storage media. The invention provides methods used in the design and identification of ligands of Site II and of modulators of nuclear hormone receptors. The invention provides ligands of Site II, modulators of NHRs, pharmaceutical compns. comprising modulators of NHRs, methods of modulating NHRs, and methods of treating diseases by administering modulators of an NHR. Also provided are methods of designing mutants, mutant NHRs, Site II binding assays, and models of Site II.

IT 650626-12-3P 650626-16-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(homol. modeling of nuclear hormone receptor Site II in ligand binding domain and design of Site II ligands)

RN 650626-12-3 CAPLUS
CN 1H-Imidazol-2-amine, 5-(4-fluoro-1-naphthalenyl)- (CA INDEX NAME)



RN 650626-16-7 CAPLUS
CN 1H-Imidazol-2-amine, 5-(6-methoxy-1-naphthalenyl)- (CA INDEX NAME)



L22 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:84008 CAPLUS
DOCUMENT NUMBER: 94:84008
ORIGINAL REFERENCE NO.: 94:13701a,13704a
TITLE: Synthesis and halogenation of some new 2-amino-4-substituted imidazoles and their possible use as pesticides
AUTHOR(S): Nath, J. P.; Mahapatra, G. N.
CORPORATE SOURCE: Dep. Chem., Ravenshaw Coll., Cuttack, 753 003, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1980), 19B(6), 526-8
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 94:84008

AB Eleven imidazoles I (R = Ph, substituted Ph, α-, β-naphthyl, 2-thienyl; R1 = H) were prepared by cyclizing RAc with guanidine using Br as condensing agent. Halogenating I (R1 = H) gave I (R1 = Br, Cl). Both halogenated and nonhalogenated imidazoles exhibit antifungal activity against Piricularia oryzae and antibacterial activity against the common pathogenic bacteria, Staphylococcus aureus and Escherichia coli. Structure-activity relationship was also discussed.

IT 76507-28-3P 76507-39-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pesticidal properties of)

RN 76507-28-3 CAPLUS
CN 1H-Imidazol-2-amine, 5-chloro-4-(1-naphthalenyl)- (CA INDEX NAME)



RN 76507-39-6 CAPLUS
CN 1H-Imidazol-2-amine, 5-bromo-4-(1-naphthalenyl)- (CA INDEX NAME)



IT 76507-18-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, halogenation and pesticidal properties of)
RN 76507-18-1 CAPLUS
CN 1H-Imidazol-2-amine, 5-(1-naphthalenyl)- (CA INDEX NAME)